content: <HTML>
  <HEAD>
       <TITLE></TITLE>
  </HEAD>
  <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>As filed with the Securities and Exchange Commission
  on June <FONT STYLE="background-color: white">20</FONT>, 2023&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Registration No. 333- __________</B>&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></P>
  
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM S-8</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT UNDER THE SECURITIES
  ACT OF 1933</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INMUNE BIO INC. </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
  its charter)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>Nevada</B></TD>
      <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>47-5205835</B></TD></TR>
  <TR>
      <TD STYLE="width: 49%">
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of</P>
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">incorporation or organization)</P></TD>
      <TD STYLE="width: 2%">&nbsp;</TD>
      <TD STYLE="width: 49%">
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(I.R.S. Employer</P>
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">identification No.)</P></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>225 NE
  Mizner Blvd.,&nbsp;Suite 640</B></FONT><B>, Boca Raton,&nbsp;FL&nbsp;33432</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B>(Address of principal executive
  offices) (Zip Code)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INmune Bio Inc. 2021 Stock Incentive Plan </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Full title of the plan)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>David Moss</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Chief Financial Officer</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INmune Bio Inc.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>225 NE
  Mizner Blvd.,&nbsp;Suite 640</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Boca Raton, FL 33432 </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name and address of agent for service)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(858) 964-3720</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Telephone number, including area code,
  of agent for service)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Copies to:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Marc Ross, Esq.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Sichenzia Ross Ference LLP</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">1185 Avenue of the Americas, 31<SUP>st</SUP>
  Floor</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">New York, New York 10036</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Phone: 212- 930-9700</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Fax: 212-930-9725</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
  is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth
  company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting
  company,&rdquo; and &quot;emerging growth company&quot; in Rule 12b-2 of the Exchange Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR>
      <TD STYLE="width: 48%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated
  filer</FONT> &nbsp;&#9744;</TD>
      <TD STYLE="width: 52%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
  filer&nbsp; &#9744;</FONT></TD></TR>
  <TR>
      <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated
  filer&nbsp; &#9746;</FONT> &nbsp;</TD>
      <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting
      company</FONT> &nbsp;&#9746;</TD></TR>
  <TR>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
  growth company &nbsp;&#9746;</FONT></TD></TR>
  <TR>
      <TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
  an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
  with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.&nbsp;</FONT>&#9744;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PART I</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Registration Statement relates to
  two separate prospectuses.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Section 10(a) Prospectus</U>: Items
  1 and 2, from this page, and the documents incorporated by reference pursuant to Part II, Item 3 of this prospectus, constitute
  a prospectus that meets the requirements of Section 10(a) of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;).</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Reoffer Prospectus</U>: The material
  that follows Item 2, up to but not including Part II of this Registration Statement, of which the reoffer prospectus is a part,
  constitutes a &ldquo;reoffer prospectus,&rdquo; prepared in accordance with the requirements of Part I of Form S-3 under the Securities
  Act. Pursuant to Instruction C of Form S-8, the reoffer prospectus may be used for reoffers or resales of shares of common stock
  which are deemed to be &ldquo;control securities&rdquo; or &ldquo;restricted securities&rdquo; under the Securities Act that have
  been acquired by the selling stockholders named in the reoffer prospectus.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 1. Plan
  Information.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">INmune Bio Inc. will provide each participant
  (the &ldquo;Recipient&rdquo;) with documents that contain information related to the INmune Bio Inc. 2021 Equity Incentive Plan (the &ldquo;2021
  Plan&rdquo; or the &ldquo;Plan&rdquo;), and other information including, but not limited to, the disclosure required by Item 1 of Form
  S-8, which information is not filed as a part of this Registration Statement on Form S-8. The foregoing information and the documents
  incorporated by reference in response to Item 3 of Part II of this Registration Statement taken together constitute a prospectus that
  meets the requirements of Section 10(a) of the Securities Act. A Section 10(a) prospectus will be given to each Recipient who receives
  shares of common stock covered by this Registration Statement, in accordance with Rule 428(b)(1) under the Securities Act.</P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 2. Registrant
  Information and Employee Plan Annual Information.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will provide to each Recipient a written
  statement advising it of the availability of documents incorporated by reference in Item 3 of Part II of this Registration Statement
  and of documents required to be delivered pursuant to Rule 428(b) under the Securities Act without charge and upon written or oral
  notice by contacting:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">INmune Bio Inc.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">225 NE Mizner Blvd., Suite
  640</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Boca Raton, FL 33432</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Attention: Corporate Secretary</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Telephone: (858) 964-3720</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Information required by Part I to be
  contained in Section 10(a) prospectus is omitted from the Registration Statement in accordance with Rule 428 under the Securities
  Act of 1933, and Note to Part I of Form S-8.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>REOFFER PROSPECTUS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INmune Bio Inc. </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>4,000,000 Shares of Common Stock</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Issued or issuable under certain awards
  granted under the Plan</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This reoffer prospectus relates to the sale of
  4,000,000 shares of our common stock that may be offered and resold from time to time by the selling stockholders identified in this prospectus
  for their own account. Such shares have been or may be acquired in connection with awards granted under the INmune Bio Inc. 2021 Equity
  Incentive Plan (the &ldquo;2021 Plan&rdquo;). It is anticipated that the selling stockholders will offer shares for sale at prevailing
  prices on the NASDAQ Capital Market on the date of sale. We will receive no part of the proceeds from sales made under this reoffer prospectus.
  The selling stockholders will bear all sales commissions and similar expenses. Any other expenses incurred by us in connection with the
  registration and offering and not borne by the selling stockholders will be borne by us.</P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This reoffer prospectus has been prepared
  for the purposes of registering the shares under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;) to allow
  for future sales by selling stockholders on a continuous or delayed basis to the public without restriction.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The selling stockholders and any brokers
  executing selling orders on their behalf may be deemed to be &ldquo;underwriters&rdquo; within the meaning of the Securities Act,
  in which event commissions received by such brokers may be deemed to be underwriting commissions under the Securities Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is quoted on the NASDAQ Capital
  Market under the symbol &ldquo;INMB.&rdquo; The last reported sale price of our common stock on the NASDAQ Capital Market on May 31, 2023,
  was $7.58 per share.</P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an &ldquo;emerging growth company&rdquo;
  as that term is used in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and, as such, have elected to comply
  with certain reduced public company reporting requirements for this prospectus supplement, the accompanying prospectus and our
  filings with the Securities and Exchange Commission.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><B>&nbsp;</B></P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investing in our common stock involves a high degree of risk. See
  &ldquo;Risk Factors&rdquo; beginning on page&nbsp;6 of this prospectus supplement. </B></P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><B>Neither the Securities and Exchange Commission nor any state
  securities commission has approved or disapproved of these securities or determined if this prospectus supplement is truthful or
  complete. Any representation to the contrary is a criminal offense. </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is June 20,
  2023.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  
  <!-- Field: Page; Sequence: 3; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>TABLE OF CONTENTS </U></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 93%">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 7%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospectus Summary</FONT></A></TD>
      <TD STYLE="text-align: center">4</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
      <TD><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</FONT></A></TD>
      <TD STYLE="text-align: center">6</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cautionary Note Regarding Forward Looking Statements</FONT></A></TD>
      <TD STYLE="text-align: center">7</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
      <TD><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Proceeds</FONT></A></TD>
      <TD STYLE="text-align: center">7</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling Stockholders</FONT></A></TD>
      <TD STYLE="text-align: center">7</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
      <TD><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan of Distribution</FONT></A></TD>
      <TD STYLE="text-align: center">10</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Matters</FONT></A></TD>
      <TD STYLE="text-align: center">12</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
      <TD><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Experts</FONT></A></TD>
      <TD STYLE="text-align: center">12</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporation of Certain Documents by Reference</FONT></A></TD>
      <TD STYLE="text-align: center">12</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
      <TD><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure of Commission Position on Indemnification For Securities Act Liabilities</FONT></A></TD>
      <TD STYLE="text-align: center">13</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional Information Available to You </FONT></A></TD>
      <TD STYLE="text-align: center">14</TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">NO PERSON HAS BEEN AUTHORIZED TO GIVE ANY INFORMATION OR TO MAKE ANY
  REPRESENTATIONS, OTHER THAN THOSE CONTAINED IN THIS PROSPECTUS, IN CONNECTION WITH THE OFFERING MADE HEREBY, AND, IF GIVEN OR MADE, SUCH
  INFORMATION OR REPRESENTATION MUST NOT BE RELIED UPON AS HAVING BEEN AUTHORIZED BY THE COMPANY OR ANY OTHER PERSON. NEITHER THE DELIVERY
  OF THIS PROSPECTUS NOR ANY SALE MADE HEREUNDER SHALL UNDER ANY CIRCUMSTANCES CREATE ANY IMPLICATION THAT THERE HAS BEEN NO CHANGE IN THE
  AFFAIRS OF THE COMPANY SINCE THE DATE HEREOF. THIS PROSPECTUS DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY
  ANY SECURITIES OFFERED HEREBY BY ANYONE IN ANY JURISDICTION IN WHICH SUCH OFFER OR SOLICITATION IS NOT AUTHORIZED OR IN WHICH THE PERSON
  MAKING SUCH OFFER OR SOLICITATION IS NOT QUALIFIED TO DO SO OR TO ANY PERSON TO WHOM IT IS UNLAWFUL TO MAKE SUCH OFFER OR SOLICITATION.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <!-- Field: Page; Sequence: 4; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <DIV STYLE="padding: 5pt; border: Black 1.5pt solid">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_002"></A>PROSPECTUS SUMMARY</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This summary highlights information contained
  elsewhere in this prospectus. You should read the entire prospectus carefully, including the section entitled &ldquo;Risk Factors&rdquo;
  before deciding to invest in our common stock. In this prospectus, the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us&rdquo; and &ldquo;our&rdquo;
  refer to INmune Bio Inc. and its subsidiaries.</P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; text-align: justify">Our objective is to develop and commercialize our product candidates
  to treat diseases where the innate immune system is not functioning normally and contributing to the patient&rsquo;s disease. This can
  be in cancer where Natural Killer (&ldquo;NK&rdquo;) cells are inactive and contribute to a tumor&rsquo;s evasion of the immune system
  and/or disease progression while expression of MUC4 and immunosuppressive cells of the tumor microenvironment proliferate to protect the
  tumor from attack by the patient&rsquo;s immune system or this can be other diseases such as neurologic and metabolic diseases where chronic
  inflammation results in innate immune system dysfunction. Our initial focus will be the treatment of cancer, treatment of Alzheimer&rsquo;s
  Disease (&ldquo;AD&rdquo;), and the treatment of Treatment Resistant Depression (&ldquo;TRD&rdquo;). In cancer, we plan to pursue two
  parallel development programs: (1) with INKmune we will initially focus on treating men with castration resistant prostate cancer and
  patients with high-risk myelodysplastic syndrome (high risk MDS); (2) with INB03, we will treat patients with cancers that express MUC4,
  a mucinous polyglucan on the surface of some epithelial cancer cells, that appears to predict resistance to immunotherapy including women
  with MUC4 expressing HER2+ breast cancer. With our XPro1595 (&ldquo;XPro&quot;) platform, we are developing therapeutics for Alzheimer&rsquo;s
  Disease and TRD. XPro for AD has completed Phase I trials and is currently enrolling patients in a Phase II trial. XPro for TRD is being
  prepared for Phase II trials. During 2021, we closed our Phase II clinical trial for treatment of pulmonary complications due to COVID-19
  infection as the Company determined it was a high-risk, low reward program due to the development of vaccinations and therapies which
  were not available when we started the clinical trial. The principal components of our strategy to achieve this objective are to:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR>
      <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">pursue development strategies and regulatory approval pathways that allow the treatment of oncology patients with our lead product candidates, INKmune and INB03;</FONT></TD></TR>
    <TR>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;&nbsp;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">pursue development strategies and regulatory approval pathways that allow the treatment of neurodegenerative diseases in patients with our lead product candidates, XPro;</FONT></TD></TR>
    <TR>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">adopt a product development strategy that solidifies our existing intellectual property (&ldquo;IP&rdquo;) to prevent competition and expand our IP suite into related immunotherapeutic areas;</FONT></TD></TR>
    <TR>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">provide clear value propositions to third-party payers, such as managed care companies or government programs like Medicare, to merit reimbursement for our product candidates; and</FONT></TD></TR>
    <TR>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Collaborate with other pharmaceutical companies with respect to, among
  other things, our INKmune and XPro platforms and other products that will benefit from development or marketing beyond our current resources.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Pursue development and regulatory approval
  pathways. </I>We believe INKmune, INB03 and XPro may be approvable under pathways that are potentially shorter than those typically available
  for drug products based on novel active ingredients, including as an orphan drug under the Orphan Drug Act and approval under the Food
  and Drug Administration (the &ldquo;FDA&rdquo;) Accelerated Approval Program (see &ldquo;Government Regulation&rdquo;). We have not yet
  had a discussion with the Medicines and Healthcare Products Regulatory Agency (&ldquo;MHRA&rdquo;) and/or FDA regarding such designation,
  but plan to do so in the future. We believe the INKmune MDS cancer program may qualify for orphan status. We believe that it would take
  a minimum of&nbsp;six months to receive Orphan Drug status once we submit an application and a minimum of 12 months to receive a designation
  once we submit an application. We might never have these discussions, submit applications under the Orphan Drug Act as the FDA Accelerated
  Approval Program or have these applications approved if we do.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Adopt a two-pronged patent strategy. </I>We
  are pursuing a two-pronged product development strategy that will seek to solidify our existing IP to prevent competition and expand our
  IP suite into related therapeutic areas. We are confident that our core in-licensed IP (see &ldquo;Intellectual Property&rdquo;) will
  allow us both freedom-to-operate and provide robust protection from outside competition. We will continue to invest in expanding our patent
  suite. We will also seek to further to strengthen our IP position by looking to in-license IP related to our focus on the innate immune
  system.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  </DIV>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>
  
  <!-- Field: Page; Sequence: 5; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <DIV STYLE="padding: 5pt; border: Black 1.5pt solid">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Provide clear value propositions to third-party
  payors to merit reimbursement for our product candidates</I>. We are designing our clinical development programs to demonstrate compelling,
  competitive advantages to patients and prescribers, and to demonstrate value propositions to third-party payors. We believe the use of
  INKmune and/or INB03 in patients with a high risk of tumor progression and death from tumor should prolong survival, improve the patient&rsquo;s
  quality of life and decrease the total cost of care for patients with these lethal malignancies. At the patient level, we believe INKmune
  and INB03 therapy, once approved, should improve survival and quality of life. At the payor level, we believe INKmune, once approved,
  should provide more predictable costs and outcomes. Therapies for Alzheimer&rsquo;s disease are needed for medical, social and economic
  reasons. The cost of Alzheimer&rsquo;s disease to the government is large and growing. The cost to families and care givers is real and
  burdensome. We believe treatment of patients with dementia, including Alzheimer&rsquo;s disease, may provide a strategy to alter the costly
  dynamic of this disease in society today.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Collaborate to maximize the value of our technology</I>.
  We believe there are two reasons for us to enter collaborations with other companies. The first is the further development of INKmune,
  INB03 and XPro by either providing additional innovations to the product, including combination therapy strategies, and/or providing resources
  to improve the speed and breadth of the development process. The second is to optimize the commercialization of our products either globally
  or regionally. The ideal partner will benefit us in both ways.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We continue to look for ways to utilize our
  unique capabilities to optimize clinical application of cell therapies. We believe that we have identified a way to manufacture
  human mesenchymal stem cells for the medical research and biotech community that offers large volumes of high-quality, low passage
  human umbilical cord mesenchymal stem cells with minimal batch-to-batch variability. We believe this may solve the problem
  associated with supplying an adequate supply of human mesenchymal stem cells for clinical applications. We have established a
  reliable supply of human umbilical cords based on our agreement with the Anthony Nolan Cord Blood Bank in the United Kingdom. We
  have developed a validated manufacturing process that reliably produces contract manufacturer of the clinical grade
  (&ldquo;cGMP&rdquo;) quality mesenchymal stem cells that we call CORDstrom. The manufacturing process can be performed at a contract
  manufacturing site under the direction of Mark Lowdell, the Company&rsquo;s Chief Scientific Officer (CSO). We will seek academic
  laboratories and biopharma companies who need a reliable source of high quality pooled human umbilical cord mesenchymal stem cells
  for research of and development of clinical products. Once identified, we plan to act as a cGMP for the development of therapeutic
  products by utilizing contract manufacturers. Because the production of the product is not continuous, we do not expect to engage a
  contract manufacturer until we have a customer identified. To date, we are supporting two academic clinical trials with CORDstrom.
  One program is a Phase 2 trial sponsored by the Great Ormond Street Children&rsquo;s Hospital in the UK treating children with
  erythematous bullousa, a disfiguring skin disease in children that is similar to a second degree burn and the second program is
  treatment of system lupus in adults. Both these studies are ongoing. INmune Bio is supplying the clinical product for treatment of
  these patients. The Company does not know the results of these trials until they are announced by the principal investigators at the
  clinical sites. We have identified contract manufacturers in the UK that have the capability to produce cGMP stem cells. We expect
  the commercial arrangement with academic laboratories or biopharma companies to be a combination of fee-for-service and licensing
  that does not require additional investment by us. We will be opportunistic in pursuing therapeutic opportunities for our own
  portfolio with this platform in the future if resources become available. The regulatory path for therapeutic applications of the
  mesenchymal stem cell products is well established and similar to the regulatory approval process for other cell therapies. We will
  only be responsible for regulatory compliance related to manufacturing of the mesenchymal stem cells when the product is being
  developed by a third party. When developing a therapeutic product for the Company&rsquo;s commercial portfolio, the Company will be
  responsible for all aspects of the regulatory process.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As previously announced
  by the Company in a press release dated on May 23, 2022, the FDA placed a full clinical hold on XPro, requesting additional information
  around the Company&rsquo;s chemistry manufacturing and controls for the treatment. The Company is working with the regulatory body to
  have the current&nbsp;hold removed as soon as possible, but it is not yet clear when the hold will be lifted. <FONT STYLE="background-color: white">If
  the FDA does not lift the clinical hold in a timely manner, or at all, our long-term development timeline for </FONT>XPro <FONT STYLE="background-color: white">and
  our business, financial condition or results of operations, may be adversely affected. The trial for XPro in Alzheimer&rsquo;s disease
  is currently open in Australia and Canada.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Information</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We were incorporated under the laws of the State
  of Nevada on September 25, 2015. Our principal executive office is located at 225 NE Mizner Blvd, Suite 640, Boca Raton FL 33432 and our
  telephone number is (858) 964-3720.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>About
  This Offering</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="background-color: white">This offering relates to the
  resale by the selling stockholders of up to 4,000,000 shares of common stock issued or issuable upon exercise of options issued pursuant
  to grants made pursuant to our 2021 Plan. </FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>
  
  </DIV>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 6; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_003"></A><B>RISK FACTORS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I Investing in our securities involves a high
  degree of risk. Before making an investment decision, you should consider carefully the risks, uncertainties and other factors described
  in our most recent Annual Report on Form 10-K, as supplemented and updated by subsequent quarterly reports on Form 10-Q and current reports
  on Form 8-K that we have filed or will file with the SEC.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">You should carefully
  consider the factors discussed in Part&nbsp;I, Item&nbsp;1A. &ldquo;Risk Factors&rdquo; in our annual report on Form&nbsp;10-K for the&nbsp;year
  ended December&nbsp;31, 2022. There have been no material changes from those risk factors. The risks discussed in our 2022 annual report
  and described below could materially affect our business, financial condition and future results.&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 7; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_004"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING
  STATEMENTS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus and the documents and information
  incorporated by reference in this prospectus contain certain forward-looking statements within the meaning of the Private Securities Litigation
  Reform Act of 1995. For this purpose, any statements contained in this prospect and the documents and information incorporated by reference
  in this prospectus that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing,
  words such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;expect,&rdquo; &ldquo;believe,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;estimate&rdquo;
  or &ldquo;continue&rdquo; or comparable terminology are intended to identify forward-looking statements. These statements by their nature
  involve substantial risks and uncertainties, and actual results may differ materially depending on a variety of factors, many of which
  are not within our control. These factors include but are not limited to economic conditions generally and in the industries in which
  we may participate; competition within our chosen industry, including competition from much larger competitors; technological advances
  and failure to successfully develop business relationships.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_005"></A>USE OF PROCEEDS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">We will not receive any
  proceeds from the sale of shares of common stock offered by the selling stockholders.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_006"></A>SELLING STOCKHOLDERS </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">This offering
  relates to the resale by the selling stockholders who have received or acquired, or may hereafter receive or acquire, the shares pursuant
  to the Plan. The selling stockholders may resell all, a portion, or none of the shares of common stock from time to time.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth, based on information
  provided to us by the selling stockholders or known to us, the name of each selling stockholder, the nature of any position, office or
  other material relationship, if any, which the selling stockholder has had, within the past three years, with us or with any of our predecessors
  or affiliates, and the number of shares of our common stock beneficially owned by the selling stockholder before this offering.&nbsp;Except
  as otherwise indicated, the selling stockholders are past or present employees or consultants of the Company. The number of shares owned
  are those beneficially owned, as determined under the rules of the SEC, and the information is not necessarily indicative of beneficial
  ownership for any other purpose.&nbsp;Under these rules, beneficial ownership includes any shares of common stock as to which a person
  has sole or shared voting power or investment power and any shares of common stock which the person has the right to acquire within 60
  days through the exercise of any option, warrant or right, through conversion of any security or pursuant to the automatic termination
  of a power of attorney or revocation of a trust, discretionary account or similar arrangement. None of the selling stockholders is a broker-dealer
  or an affiliate of a broker-dealer. Percentage of ownership is based on 17,945,995 shares of common stock outstanding on June 5, 2023.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">We have assumed all shares of common stock reflected on the table will
  be sold from time to time in the offering covered by this prospectus.&nbsp;Because the selling stockholders may offer all or any portion
  of the shares of common stock listed in the table below, no estimate can be given as to the amount of those shares of common stock covered
  by this prospectus that will actually be held by the selling stockholders upon the termination of the offering. Selling stockholders may
  choose not to sell any of the shares of common stock registered herein.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 8; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Number of Shares</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Beneficially Owned<BR>
      Prior to Offering (1)</B></P></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of <BR>
  Shares Being</B></FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Shares <BR>
  Beneficially Owned <BR>
  After Offering</B></FONT></TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Selling Stockholder</B></FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position</B></FONT></TD>
      <TD>&nbsp;</TD>
      <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number</B></FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percent <BR>
  (%)</B></FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Offered</B></FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number</B></FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percent <BR>
  (%)</B></FONT></TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; width: 17%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raymond J. Tesi</FONT></TD>
      <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President, CEO and Director</FONT></TD>
      <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,322,364</FONT></TD>
      <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.4</FONT></TD>
      <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
      <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">94,581</FONT></TD>
      <TD STYLE="vertical-align: bottom; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
      <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,227,783</FONT></TD>
      <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.9</FONT></TD>
      <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Moss</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CFO, Treasurer and Secretary</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,056,817</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.0</FONT></TD>
      <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">94,581</FONT></TD>
      <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,962,236</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</FONT></TD>
      <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark Lowdell</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CSO</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,122,605</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.4</FONT></TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46,222</FONT></TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,076,383</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.2</FONT></TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher Barnum</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Head of Neuroscience</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">293,333</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.6</FONT></TD>
      <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">93,333</FONT></TD>
      <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">200,000</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></TD>
      <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%&nbsp;</FONT></TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Josh Schoonover</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assoc. General Counsel</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">281,266</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5</FONT></TD>
      <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">86,666</FONT></TD>
      <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">194,600</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></TD>
      <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%&nbsp;</FONT></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cory Ellspermann</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controller and VP of Finance</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">115,917</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,000</FONT></TD>
      <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">75,917</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tara Lehner</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VP of Clinical Operations </FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54,667</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54,667 </FONT></TD>
      <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parris Pope</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Head of Medical Affairs</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38,889</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38,889</FONT></TD>
      <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kim Staats</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director of Rare Disease Drug Development</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000</FONT></TD>
      <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary Cai</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice President of Regulatory Affairs</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,833</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,833 </FONT></TD>
      <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scott Juda</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">287,550</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.6</FONT></TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,238</FONT></TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">259,312</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4</FONT></TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%&nbsp;</FONT></TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Timothy Schroeder</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">349,737</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.9</FONT></TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,238</FONT></TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">321,499</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.8</FONT></TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%&nbsp;</FONT></TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">J. Kelly Ganjei</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">275,343</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5</FONT></TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,238</FONT></TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">247,105</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4</FONT></TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%&nbsp;</FONT></TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Edgardo Baracchini</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">149,550</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,238</FONT></TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">121,312</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marcia Allen</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
      <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">149,550</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
      <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,238</FONT></TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
      <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">121,312</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="border-bottom: black 4.5pt double">&nbsp;</TD>
      <TD STYLE="border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,533,421</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: right">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="border-bottom: black 4.5pt double">&nbsp;</TD>
      <TD STYLE="border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">725,962</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="border-bottom: black 4.5pt double">&nbsp;</TD>
      <TD STYLE="border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,807,459</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: right">&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="background-color: white">*</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white">Less than 1%</FONT></TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"></FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="background-color: white">(1)</FONT></TD><TD STYLE="text-align: justify">The securities &ldquo;beneficially owned&rdquo; by a person
  are determined in accordance with the definition of &ldquo;beneficial ownership&rdquo; set forth in the rules and regulations promulgated
  under the Exchange Act, and accordingly, may include securities owned by and for, among others, the spouse and/or minor children of an
  individual and any other relative who has the same home as such individual, as well as other securities as to which the individual has
  or shares voting or investment power or which such person has the right to acquire within 60 days of June 5, 2023 pursuant to the
  exercise of options, or otherwise. Beneficial ownership may be disclaimed as to certain of the securities.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0px">&nbsp;</TD>
      <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">(2)</FONT></TD>
      <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Includes: (a) options to purchase 70,663 shares of common stock exercisable at an exercise price of $17.49 per share pursuant to the 2021 Plan, of which options to purchase 36,803 shares are vested and (b) options to purchase 130,000 shares of common stock exercisable at an exercise price of $7.92 per share pursuant to the 2021 Plan, of which options to purchase 57,778 shares are vested.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0px">&nbsp;</TD>
      <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">(3)</FONT></TD>
      <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes options to purchase 104,000 shares of common stock exercisable at an exercise price of $7.92 per share pursuant to the 2021 Plan, of which options to purchase 46,222 shares are vested.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0px">&nbsp;</TD>
      <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">(4)</FONT></TD>
      <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes: (a) options to purchase 100,000 shares of common stock exercisable at an exercise price of $21.06 per share pursuant to the 2021 Plan, of which options to purchase 66,667 shares are vested; and (b) options to purchase 60,000 shares of common stock at an exercise price of $7.92 per share pursuant to the 2021 Plan, of which options to purchase 26,666 shares are vested.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0px">&nbsp;</TD>
      <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">(5)</FONT></TD>
      <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes: (a) options to purchase 90,000 shares of common stock exercisable at an exercise price of $21.06 per share pursuant to the 2021 Plan, of which options to purchase 60,000 shares are vested; and (b) options to purchase 60,000 shares of common stock at an exercise price of $7.92 per share pursuant to the 2021 Plan, of which options to purchase 26,666 shares are vested.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 9; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="background-color: white">(6)</FONT></TD><TD STYLE="text-align: justify">Includes: (a) options to purchase 40,000 shares of common
  stock exercisable at an exercise price of $21.06 per share pursuant to the 2021 Plan, of which options to purchase 26,666 shares are
  vested and (b) options to purchase 30,000 shares of common stock exercisable at an exercise price of $7.92 per share pursuant to the
  2021 Plan, of which options to purchase 13,334 shares are vested.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="background-color: white">(7)</FONT></TD><TD STYLE="text-align: justify">Includes: a) options to purchase 58,000 shares of common
  stock exercisable at an exercise price of $18.40 per share pursuant to the 2021 Plan, of which options to purchase 45,778 shares are
  vested and (b) options to purchase 20,000 shares of common stock exercisable at an exercise price of $7.92 per share pursuant to the
  2021 Plan, of which options to purchase 8,889 shares are vested.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="background-color: white">(8)</FONT></TD><TD STYLE="text-align: justify">Includes: a) options to purchase 45,000 shares of common
  stock exercisable at an exercise price of $21.06 per share pursuant to the 2021 Plan, of which options to purchase 30,000 shares are
  vested and (b) options to purchase 30,000 shares of common stock exercisable at an exercise price of $7.92 per share pursuant to the
  2021 Plan, of which options to purchase 8,889 shares are vested.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="background-color: white">(9)</FONT></TD><TD STYLE="text-align: justify">Includes options to purchase 50,000 shares of common stock
  exercisable at an exercise price of $9.67 per share pursuant to the 2021 Plan of which options to purchase 25,000 shares are vested.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="background-color: white">(10)</FONT></TD><TD STYLE="text-align: justify">Includes options to purchase 30,000 shares of common stock
  exercisable at an exercise price of $7.36 per share pursuant to the 2021 Plan of which options to purchase 10,833 shares are vested.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="background-color: white">(11)</FONT></TD><TD STYLE="text-align: justify">Includes: (a) options to purchase 19,025 shares of common
  stock exercisable by pursuant to the 2021 Plan, of which options to purchase 12,683 shares are vested and (b) options to purchase 35,000
  shares of common stock exercisable at an exercise price of $7.92 per share pursuant to the 2021 Plan, of which options to purchase 15,555
  shares are vested.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 10; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>
  
  <P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/107% Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B><A NAME="a_007"></A>PLAN OF DISTRIBUTION</B></P>
  
  <P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Timing of Sales</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The
  selling stockholders may offer and sell the shares covered by this prospectus at various times. The selling stockholders will act
  independently of our company in making decisions with respect to the timing, manner and size of each sale.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To our knowledge, no selling stockholder has
  any agreement or understanding, directly or indirectly, with any person to resell the shares of common stock covered by this prospectus.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Offering Price</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The sales price offered by the selling
  stockholders to the public may be:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in">&nbsp;</TD>
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the market price prevailing at the time of sale;</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 50pt; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in">&nbsp;</TD>
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a price related to such prevailing market price; or</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in">&nbsp;</TD>
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">such other price as the selling stockholders determine from time to time.</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Manner of Sale </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The shares of common stock may be sold
  by means of one or more of the following methods:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in">&nbsp;</TD>
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a block trade in which the broker-dealer so engaged will attempt to sell the shares of common stock as agent, but may position and resell a portion of the block as principal to facilitate the transaction;</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 50pt; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in">&nbsp;</TD>
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases by a broker-dealer as principal and resale by that broker-dealer for its account pursuant to this prospectus;</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in">&nbsp;</TD>
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary brokerage transactions in which the broker solicits purchasers;</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in">&nbsp;</TD>
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through options, swaps or derivatives;</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in">&nbsp;</TD>
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in transactions to cover short sales;</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in">&nbsp;</TD>
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">privately negotiated transactions; or</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in">&nbsp;</TD>
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in a combination of any of the above methods.</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The selling stockholders may sell their
  shares of common stock directly to purchasers or may use brokers, dealers, underwriters or agents to sell their shares of common
  stock. Brokers or dealers engaged by the selling stockholders may arrange for other brokers or dealers to participate. Brokers
  or dealers may receive commissions, discounts or concessions from the selling stockholders, or, if any such broker-dealer acts
  as agent for the purchaser of shares of common stock, from the purchaser in amounts to be negotiated immediately prior to the sale.
  The compensation received by brokers or dealers may, but is not expected to, exceed that which is customary for the types of transactions
  involved.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Broker-dealers may agree with a selling stockholder to sell a specified
  number of shares of common stock at a stipulated price per common share, and, to the extent the broker-dealer is unable to do so acting
  as agent for a selling stockholder, to purchase as principal any unsold shares of common stock at the price required to fulfill the broker-dealer
  commitment to the selling stockholder.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Broker-dealers who acquire shares of common
  stock as principal may thereafter resell the shares of common stock from time to time in transactions, which may involve block
  transactions and sales to and through other broker-dealers, including transactions of the nature described above, on the NASDAQ
  Capital Market or otherwise at prices and on terms then prevailing at the time of sale, at prices then related to the then-current
  market price or in negotiated transactions. In connection with resales of the shares of common stock, broker-dealers may pay to
  or receive from the purchasers of shares commissions as described above.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>
  
  <!-- Field: Page; Sequence: 11; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the selling stockholders enter into
  arrangements with brokers or dealers, as described above, we are obligated to file a post-effective amendment to this registration
  statement disclosing such arrangements, including the names of any broker-dealers acting as underwriters.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The selling stockholders and any broker-dealers
  or agents that participate with the selling stockholders in the sale of the shares of common stock may be deemed to be &ldquo;underwriters&rdquo;
  within the meaning of the Securities Act. In that event, any commissions received by broker-dealers or agents and any profit on
  the resale of the shares of common stock purchased by them may be deemed to be underwriting commissions or discounts under the
  Securities Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sales Pursuant to Rule 144</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any shares of common stock covered by this
  prospectus which qualify for sale pursuant to Rule 144 under the Securities Act may be sold under Rule 144 rather than pursuant
  to this prospectus.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Regulation&nbsp;M</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The selling stockholders must comply with
  the requirements of the Securities Act and the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;) in
  the offer and sale of the common stock. In particular we will advise the selling stockholders that the anti-manipulation rules
  of Regulation&nbsp;M under the Exchange Act may apply to sales of shares of common stock in the market and to the activities of
  the selling stockholders and their affiliates. Regulation&nbsp;M under the Exchange Act prohibits, with certain exceptions, participants
  in a distribution from bidding for, or purchasing for an account in which the participant has a beneficial interest, any of the
  securities that are the subject of the distribution.&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accordingly, during such times as a selling
  stockholder may be deemed to be engaged in a distribution of the common stock, and therefore be considered to be an underwriter,
  the selling stockholder must comply with applicable law and, among other things:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in">&nbsp;</TD>
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may not engage in any stabilization activities in connection with our common stock;</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in">&nbsp;</TD>
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may not cover short sales by purchasing shares while the distribution is taking place; and</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in">&nbsp;</TD>
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities other than as permitted under the Exchange Act.</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we will make copies of this
  prospectus available to the selling stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities
  Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>State Securities Laws</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the securities laws of some states,
  the shares of common stock may be sold in such states only through registered or licensed brokers or dealers. In addition, in some
  states the shares of common stock may not be sold unless the shares have been registered or qualified for sale in the state or
  an exemption from registration or qualification is available and is complied with.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Expenses of Registration</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are bearing all costs relating to the
  registration of the common stock. The selling stockholders, however, will pay any commissions or other fees payable to brokers
  or dealers in connection with any sale of the common stock.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>
  
  <!-- Field: Page; Sequence: 12; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_008"></A>LEGAL MATTERS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The validity of the common stock has been
  passed upon by Sichenzia Ross Ference LLP, New York, New York.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_009"></A>EXPERTS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements of INmune
  Bio Inc. as of and for the years ended December&nbsp;31, 2022 and 2021 appearing in INmune Bio Inc.&rsquo;s Definitive Proxy Statement
  on Schedule A for the year ended December&nbsp;31, 2022, have been audited by Marcum LLP, as set forth in its report thereon, included
  therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance
  upon such report given on the authority of such firm as experts in accounting and auditing.&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_010"></A>INCORPORATION
  OF CERTAIN DOCUMENTS by Reference</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Securities and Exchange Commission, or SEC,
  allows us to incorporate by reference certain of our publicly filed documents into this prospectus, which means that such information
  is considered part of this prospectus. Information that we file with the SEC subsequent to the date of this prospectus will automatically
  update and supersede this information. We incorporate by reference the documents listed below and any future filings made with the SEC
  under all documents subsequently filed by us pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act until the selling stockholders
  have sold all of the shares offered hereby or such shares have been deregistered.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 24px">&nbsp;</TD>
      <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our Annual Report on <A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000121390023016875/f10k2022_inmunebioinc.htm">Form 10-K</A> for the fiscal year ended December 31, 2022, filed with the SEC on March 2, 2023;</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our Quarterly Report on <A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000121390023035972/f10q0323_inmunebio.htm">Form 10-Q</A> for the period ended March 31, 2023, filed with the SEC on May 3, 2023; </FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 24px">&nbsp;</TD>
      <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our Current Reports on Form 8-K or Form 8-K/A filed with the SEC on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1711754/000121390023004991/ea172117-8k_inmunebio.htm">January
      25, 2023</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1711754/000121390023009995/ea173121-8k_inmunebio.htm">February
      10, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1711754/000121390023013650/ea173958-8k_inmunebio.htm">February
      22, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1711754/000121390023013652/ea174111-8k_inmunebio.htm">February
      22, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1711754/000121390023020297/ea175256-8k_inmune.htm">March 15,
      2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1711754/000121390023025893/ea176035-8k_inmune.htm">April 3,
      2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1711754/000121390023028837/ea176788-8k_inmunebio.htm">April 11,
      2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1711754/000121390023031332/ea177097-8k_inmunebio.htm">April 20,
      2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1711754/000121390023032007/ea177365-8k_inmunebio.htm">April 24,
      2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1711754/000121390023037092/ea178099-8k_inmunebio.htm">May 8, 2023</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1711754/000121390023038732/ea178382-8k_inmune.htm">May 12, 2023</A>, and <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1711754/000121390023044983/ea178909-8k_inmune.htm">June 1, 2023</A></FONT>.</TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 24px">&nbsp;</TD>
      <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our Definitive Proxy Statement on <A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000121390023031675/def14a0423_inmunebioinc.htm">Schedule 14A</A> filed with the SEC on April 21, 2023; and</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
      <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the description of our common stock, which is contained in the registration statement on <A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000164033419000136/inmune_8a12b.htm">Form 8-A</A> filed with the SEC on February 1, 2019 (File No. 001-38793), including any amendments or reports filed for the purpose of updating that description.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding the foregoing, information furnished
  under Items 2.02 and 7.01 of any Current Report on Form 8-K, including the related exhibits, is not incorporated by reference in this
  Registration Statement.</P>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 13; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_011"></A>Disclosure
  Of Commission Position On Indemnification </B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>For
  Securities Act Liabilities</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NRS 78.7502(1) provides that a corporation may
  indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or
  proceeding, whether civil, criminal, administrative or investigative, except an action by or in the right of the corporation, by reason
  of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation
  as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses,
  including attorneys&rsquo; fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection
  with the action, suit or proceeding if he: (a) is not liable pursuant to NRS 78.138; or (b) acted in good faith and in a manner which
  he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding,
  had no reasonable cause to believe his conduct was unlawful.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NRS Section 78.7502(2) provides that a corporation
  may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit
  by or in the right of the corporation to procure a judgment in its favor by reason of the fact that he is or was a director, officer,
  employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent
  of another corporation, partnership, joint venture, trust or other enterprise against expenses, including amounts paid in settlement and
  attorneys&rsquo; fees actually and reasonably incurred by him in connection with the defense or settlement of the action or suit if he:
  (a) is not liable pursuant to NRS 78.138; or (b) acted in good faith and in a manner which he reasonably believed to be in or not opposed
  to the best interests of the corporation. Indemnification may not be made for any claim, issue or matter as to which such a person has
  been adjudged by a court of competent jurisdiction, after exhaustion of all appeals there from, to be liable to the corporation or for
  amounts paid in settlement to the corporation, unless and only to the extent that the court in which the action or suit was brought or
  other court of competent jurisdiction determines upon application that in view of all the circumstances of the case, the person is fairly
  and reasonably entitled to indemnity for such expenses as the court deems proper.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Articles of Incorporation provides that every
  person who was or is a party to, or is threatened to be made a party to, or is involved in any action, suit or proceeding, whether civil,
  criminal, administrative or investigative, by reason of the fact that he, or a person of whom he is the legal representative, is or was
  a director or officer of the Company, or is or was serving at the request of the Company as a director or officer of another corporation,
  or as its representative in a partnership, joint venture, trust or other enterprise, shall be indemnified and held harmless to the fullest
  extent legally permissible under the laws of the State of Nevada from time to time against all expenses, liability and loss (including
  attorney&rsquo;s fees, judgements, fines and amounts paid or to be paid in settlement) reasonably incurred or suffered by him in connection
  therewith. Such right of indemnification shall be a contract right which may be enforced in any matter desired by such person. The expenses
  of the officers and directors incurred in defending a civil or criminal action, suit or proceeding must be paid by the Company as they
  are incurred and in advance of the final disposition of the action, suit or proceeding, upon receipt of an undertaking by or on behalf
  of the director or officer to repay the amount if it is ultimately determined by a court of competent jurisdiction that he is not entitled
  to be indemnified by the Company. Such right of indemnification shall not be exclusive of any other right which such directors, officers
  or representatives may have or hereafter acquire, and, without limiting the generality of such statement, they shall be entitled to their
  respective rights of indemnification under any bylaw, agreement, vote of stockholders, provision of law, or otherwise, as well as their
  rights under this Article.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NRS Section 78.747 provides that except as otherwise
  provided by specific statute, no director or officer of a corporation is individually liable for a debt or liability of the corporation,
  unless the director or officer acts as the alter ego of the corporation. The court as a matter of law must determine the question of whether
  a director or officer acts as the alter ego of a corporation.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insofar as indemnification for liabilities arising
  under the Securities Act may be permitted to directors, offices or controlling persons of ours, pursuant to the foregoing provisions,
  or otherwise, we have been advised that, in the opinion of the Securities and Exchange Commission, such indemnification is against public
  policy as expressed in the Securities Act, and is, therefore, unenforceable. In the event that a claim for indemnification against such
  liabilities (other than the payment by us of expenses incurred or paid by a director, officer or controlling person of ours in the successful
  defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities
  being registered hereunder, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit
  to a court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Securities
  Act and will be governed by the final adjudication of such issue.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 14; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_012"></A><FONT STYLE="text-transform: uppercase"><B>Additional
  Information Available to You</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus is part of a Registration Statement
  on Form S-8 that we filed with the SEC. Certain information in the Registration Statement has been omitted from this prospectus in accordance
  with the rules of the SEC. We file annual, quarterly and special reports, proxy statements and other information with the SEC. You can
  inspect and copy the Registration Statement as well as reports, proxy statements and other information we have filed with the SEC at the
  public reference room maintained by the SEC at 100 F Street N.E. Washington, D.C. 20549, You can obtain copies from the public reference
  room of the SEC at 100 F Street N.E. Washington, D.C. 20549, upon payment of certain fees. You can call the SEC at 1-800-732-0330 for
  further information about the public reference room. We are also required to file electronic versions of these documents with the SEC,
  which may be accessed through the SEC&rsquo;s World Wide Web site at http://www.sec.gov. No dealer, salesperson or other person is authorized
  to give any information or to make any representations other than those contained in this prospectus, and, if given or made, such information
  or representations must not be relied upon as having been authorized by us. This prospectus does not constitute an offer to buy any security
  other than the securities offered by this prospectus, or an offer to sell or a solicitation of an offer to buy any securities by any person
  in any jurisdiction where such offer or solicitation is not authorized or is unlawful. Neither delivery of this prospectus nor any sale
  hereunder shall, under any circumstances, create any implication that there has been no change in the affairs of our company since the
  date hereof.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 15; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION REQUIRED IN THE REGISTRATION
  STATEMENT </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 3. Incorporation of Documents by
  Reference.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Securities and Exchange Commission, or SEC, allows
  us to incorporate by reference certain of our publicly filed documents into this prospectus, which means that such information is considered
  part of this prospectus. Information that we file with the SEC subsequent to the date of this prospectus will automatically update and
  supersede this information. We incorporate by reference the documents listed below and any future filings made with the SEC under all
  documents subsequently filed by us pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act until the selling stockholders have
  sold all of the shares offered hereby or such shares have been deregistered.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
      <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our Annual Report on <A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000121390023016875/f10k2022_inmunebioinc.htm">Form 10-K</A> for the fiscal year ended December 31, 2022, filed with the SEC on March 2, 2023;</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our Quarterly Report on <A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000121390023035972/f10q0323_inmunebio.htm">Form 10-Q</A> for the period ended March 31, 2023, filed with the SEC on May 3, 2023; </FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 24px">&nbsp;</TD>
      <TD STYLE="text-align: justify; width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our Current Reports on Form 8-K or Form 8-K/A filed with the SEC on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1711754/000121390023004991/ea172117-8k_inmunebio.htm">January
      25, 2023</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1711754/000121390023009995/ea173121-8k_inmunebio.htm">February
      10, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1711754/000121390023013650/ea173958-8k_inmunebio.htm">February
      22, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1711754/000121390023013652/ea174111-8k_inmunebio.htm">February
      22, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1711754/000121390023020297/ea175256-8k_inmune.htm">March 15,
      2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1711754/000121390023025893/ea176035-8k_inmune.htm">April 3,
      2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1711754/000121390023028837/ea176788-8k_inmunebio.htm">April 11,
      2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1711754/000121390023031332/ea177097-8k_inmunebio.htm">April 20,
      2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1711754/000121390023032007/ea177365-8k_inmunebio.htm">April 24,
      2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1711754/000121390023037092/ea178099-8k_inmunebio.htm">May 8, 2023</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1711754/000121390023038732/ea178382-8k_inmune.htm">May 12, 2023</A>, and <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1711754/000121390023044983/ea178909-8k_inmune.htm">June 1, 2023</A></FONT>.</TD></TR>
  </TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
      <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our Definitive Proxy Statement on <A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000121390023031675/def14a0423_inmunebioinc.htm">Schedule 14A</A> filed with the SEC on April 21, 2023; and</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
      <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the description of our common stock, which is contained in the registration statement on <A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000164033419000136/inmune_8a12b.htm">Form 8-A</A> filed with the SEC on February 1, 2019 (File No. 001-38793), including any amendments or reports filed for the purpose of updating that description.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Notwithstanding the foregoing, information furnished
  under Items 2.02 and 7.01 of any Current Report on Form 8-K, including the related exhibits, is not incorporated by reference in this
  Registration Statement.</P>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 4. Description of Securities.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 5. Interests of Named Experts and
  Counsel.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>
  
  <!-- Field: Page; Sequence: 16; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 6. Indemnification of Directors
  and Officers.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NRS 78.7502(1) provides that a corporation may
  indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or
  proceeding, whether civil, criminal, administrative or investigative, except an action by or in the right of the corporation, by reason
  of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation
  as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses,
  including attorneys&rsquo; fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection
  with the action, suit or proceeding if he: (a) is not liable pursuant to NRS 78.138; or (b) acted in good faith and in a manner which
  he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding,
  had no reasonable cause to believe his conduct was unlawful.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NRS Section 78.7502(2) provides that a corporation
  may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit
  by or in the right of the corporation to procure a judgment in its favor by reason of the fact that he is or was a director, officer,
  employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent
  of another corporation, partnership, joint venture, trust or other enterprise against expenses, including amounts paid in settlement and
  attorneys&rsquo; fees actually and reasonably incurred by him in connection with the defense or settlement of the action or suit if he:
  (a) is not liable pursuant to NRS 78.138; or (b) acted in good faith and in a manner which he reasonably believed to be in or not opposed
  to the best interests of the corporation. Indemnification may not be made for any claim, issue or matter as to which such a person has
  been adjudged by a court of competent jurisdiction, after exhaustion of all appeals there from, to be liable to the corporation or for
  amounts paid in settlement to the corporation, unless and only to the extent that the court in which the action or suit was brought or
  other court of competent jurisdiction determines upon application that in view of all the circumstances of the case, the person is fairly
  and reasonably entitled to indemnity for such expenses as the court deems proper.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Articles of Incorporation provides that every
  person who was or is a party to, or is threatened to be made a party to, or is involved in any action, suit or proceeding, whether civil,
  criminal, administrative or investigative, by reason of the fact that he, or a person of whom he is the legal representative, is or was
  a director or officer of the Company, or is or was serving at the request of the Company as a director or officer of another corporation,
  or as its representative in a partnership, joint venture, trust or other enterprise, shall be indemnified and held harmless to the fullest
  extent legally permissible under the laws of the State of Nevada from time to time against all expenses, liability and loss (including
  attorney&rsquo;s fees, judgements, fines and amounts paid or to be paid in settlement) reasonably incurred or suffered by him in connection
  therewith. Such right of indemnification shall be a contract right which may be enforced in any matter desired by such person. The expenses
  of the officers and directors incurred in defending a civil or criminal action, suit or proceeding must be paid by the Company as they
  are incurred and in advance of the final disposition of the action, suit or proceeding, upon receipt of an undertaking by or on behalf
  of the director or officer to repay the amount if it is ultimately determined by a court of competent jurisdiction that he is not entitled
  to be indemnified by the Company. Such right of indemnification shall not be exclusive of any other right which such directors, officers
  or representatives may have or hereafter acquire, and, without limiting the generality of such statement, they shall be entitled to their
  respective rights of indemnification under any bylaw, agreement, vote of stockholders, provision of law, or otherwise, as well as their
  rights under this Article.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NRS Section 78.747 provides that except as otherwise
  provided by specific statute, no director or officer of a corporation is individually liable for a debt or liability of the corporation,
  unless the director or officer acts as the alter ego of the corporation. The court as a matter of law must determine the question of whether
  a director or officer acts as the alter ego of a corporation.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insofar as indemnification for liabilities arising
  under the Securities Act may be permitted to directors, offices or controlling persons of ours, pursuant to the foregoing provisions,
  or otherwise, we have been advised that, in the opinion of the Securities and Exchange Commission, such indemnification is against public
  policy as expressed in the Securities Act, and is, therefore, unenforceable. In the event that a claim for indemnification against such
  liabilities (other than the payment by us of expenses incurred or paid by a director, officer or controlling person of ours in the successful
  defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities
  being registered hereunder, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit
  to a court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Securities
  Act and will be governed by the final adjudication of such issue.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;&nbsp;</B></P>
  
  <!-- Field: Page; Sequence: 17; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 7. Exemption from Registration
  Claimed.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 8. Exhibits.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit Number</B></FONT></TD>
      <TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center; border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; width: 90%"><B>Description</B></TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="ea178321ex5-1_inmune.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Sichenzia Ross Ference LLP*</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea178321ex23-1_inmune.htm">Consent of Marcum LLP*</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="ea178321ex5-1_inmune.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Sichenzia Ross Ference LLP (included in Exhibit 5.1)*</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of Attorney (included on the signature page)</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1 </FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000121390021030752/ea142128ex10-1_inmunebioinc.htm">INmune Bio Inc. 2021 Stock Incentive Plan (incorporated by reference to the Current Report on Form 8-K filed with the SEC on June 3, 2021).</A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD>107</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="ea178321ex-fee_inmune.htm">Filing Fee Table*</A></TD></TR>
    </TABLE>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;*</FONT></TD>
      <TD STYLE="width: 96%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 9. Undertakings.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0px"></TD>
      <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company hereby undertakes:</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
      <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
      <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act.</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
      <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered&nbsp;&nbsp;would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the &ldquo;Calculation of Registration Fee&rdquo; table in the effective Registration Statement.</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>
  
  <!-- Field: Page; Sequence: 18; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
      <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement; provided, however, that (A)&nbsp;paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the Registration Statement is on Form S&ndash;8 (&sect;239.16b of Regulation S-K), and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Securities and Exchange Commission by the Company pursuant to section 13 or section 15(d) of the Exchange Act (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in the Registration Statement; and (B)&nbsp;paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) do not apply if the Registration Statement is on Form S-3 or Form F-3, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Securities and Exchange Commission by the Company pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act that are incorporated by reference in the Registration Statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the Registration Statement; provided further, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the Registration Statement is for an offering of asset-backed securities on Form S-1 or Form S-3, and the information required to be included in a post-effective amendment is provided pursuant to Item&nbsp;1100(c) of Regulation AB.</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
      <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
      <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
      <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(A)&nbsp;Each prospectus
  filed by a Registrant pursuant to Rule&nbsp;424(b)(3) shall be deemed to be part of the registration statement as of the date the
  filed prospectus was deemed part of and included in the registration statement; and</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(B)&nbsp;Each prospectus
  required to be filed pursuant to Rule&nbsp;424(b)(2), (b)(5) or (b)(7) as part of a registration statement in reliance on Rule&nbsp;430B
  relating to an offering made pursuant to Rule&nbsp;415(a)(1)(i),&nbsp;&nbsp;(vii)&nbsp;or (x)&nbsp;for the purpose of providing
  the information required by Section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration
  statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract
  of sale of securities in the offering described in the prospectus. As provided in Rule&nbsp;430B, for liability purposes of the
  issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration
  statement relating to the securities in the registration statement to which the prospectus relates, and the offering of such securities
  at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration
  statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by
  reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with
  a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement
  or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0px"></TD>
      <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Company&rsquo;s annual report pursuant to Section&nbsp;13(a) or Section&nbsp;15(d) of the Exchange Act that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0px"></TD>
      <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Company pursuant to the foregoing provisions, or otherwise, the Company has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Company of expenses incurred or paid by a director, officer or controlling person of the Company in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Company will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>
  
  <!-- Field: Page; Sequence: 19; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_001"></A><B>SIGNATURES </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="background-color: white"></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">Pursuant
  to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all
  of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned,
  thereunto duly authorized, in the City of Boca Raton, State of Florida, on June 20, 2023.</FONT></P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white"></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 60%">&nbsp;</TD>
      <TD STYLE="width: 40%">
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>INmune Bio Inc. </B></P>
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Raymond J. Tesi</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raymond J. Tesi, M. D. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ David J. Moss</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David J. Moss</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>
  
  <!-- Field: Page; Sequence: 20; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each person whose signature appears below
  constitutes and appoints Raymond J. Tesi and David J. Moss, and each of them severally, as his true and lawful attorney in fact
  and agent, with full powers of substitution and re-substitution, for him and in his name, place and stead, in any and all capacities,
  to sign any or all amendments (including post effective amendments) to the Registration Statement, and to sign any registration
  statement for the same offering covered by this Registration Statement that is to be effective upon filing pursuant to Rule 462(b)
  under the Securities Act of 1933, as amended, and all post effective amendments thereto, and to file the same, with all exhibits
  thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact
  and agent, each acting alone, full power and authority to do and perform each and every act and thing requisite and necessary to
  be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying
  and confirming all that said attorney-in-fact and agent, each acting alone, or his or her substitute or substitutes, may lawfully
  do or cause to be done by virtue hereof.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
  Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the dates indicated.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 40%; border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Raymond J. Tesi</FONT></TD>
      <TD STYLE="width: 35%; text-align: justify">&nbsp;</TD>
      <TD STYLE="width: 25%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 20, 2023</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raymond J. Tesi, M.D. </FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and&nbsp;Director<BR>
  (principal executive officer)</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ David J. Moss</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 20, 2023</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David J. Moss</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(principal financial and accounting officer)</P></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Timothy Schroeder</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 20, 2023</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Timothy Schroeder</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ J. Kelly Ganjei</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 20, 2023</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">J. Kelly Ganjei </FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Scott Juda, JD</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 20, 2023</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scott Juda, JD</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Edgardo Baracchini</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 20, 2023</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Edgardo Baracchini</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Marcia Allen</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 20, 2023</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marcia Allen</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    </TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <!-- Field: Page; Sequence: 21; Options: Last -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  </BODY>
  </HTML>
metadata_documents: [{"type": "S-8", "sequence": "1", "filename": "ea178321-s8_inmunebioinc.htm", "description": "REGISTRATION STATEMENT", "secsgml_size_bytes": 184693}]
metadata_filer: {"company-data": {"conformed-name": "Inmune Bio, Inc.", "cik": "0001711754", "assigned-sic": "2836", "irs-number": "475205835", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-272770", "film-number": "231024943"}, "business-address": {"street1": "225 NE MIZNER BLVD, SUITE 640", "city": "BOCA RATON", "state": "FL", "zip": "33432", "phone": "8589643720"}, "mail-address": {"street1": "225 NE MIZNER BLVD, SUITE 640", "city": "BOCA RATON", "state": "FL", "zip": "33432"}}
text: As filed with the Securities and Exchange Commission
  on June
  20
  , 2023
  Registration No. 333- __________
  UNITED STATES
  SECURITIES AND EXCHANGE COMMISSION
  Washington, D.C. 20549
  FORM S-8
  REGISTRATION STATEMENT UNDER THE SECURITIES
  ACT OF 1933
  INMUNE BIO INC.
  (Exact name of registrant as specified in
  its charter)
  Nevada
  47-5205835
  (State or other jurisdiction of
  incorporation or organization)
  (I.R.S. Employer
  identification No.)
  225 NE
  Mizner Blvd., Suite 640
  , Boca Raton, FL 33432
  (Address of principal executive
  offices) (Zip Code)
  INmune Bio Inc. 2021 Stock Incentive Plan
  (Full title of the plan)
  David Moss
  Chief Financial Officer
  INmune Bio Inc.
  225 NE
  Mizner Blvd., Suite 640
  Boca Raton, FL 33432
  (Name and address of agent for service)
  (858) 964-3720
  (Telephone number, including area code,
  of agent for service)
  Copies to:
  Marc Ross, Esq.
  Sichenzia Ross Ference LLP
  1185 Avenue of the Americas, 31
  st
  Floor
  New York, New York 10036
  Phone: 212- 930-9700
  Fax: 212-930-9725
  Indicate by check mark whether the registrant
  is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth
  company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting
  company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
  Large accelerated
  filer
  ☐
  Accelerated
  filer  ☐
  Non-accelerated
  filer  ☒
  Smaller reporting
      company
  ☒
  Emerging
  growth company  ☒
  If
  an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
  with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
  ☐
  PART I
  INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
  This Registration Statement relates to
  two separate prospectuses.
  Section 10(a) Prospectus
  : Items
  1 and 2, from this page, and the documents incorporated by reference pursuant to Part II, Item 3 of this prospectus, constitute
  a prospectus that meets the requirements of Section 10(a) of the Securities Act of 1933, as amended (the "Securities Act").
  Reoffer Prospectus
  : The material
  that follows Item 2, up to but not including Part II of this Registration Statement, of which the reoffer prospectus is a part,
  constitutes a "reoffer prospectus," prepared in accordance with the requirements of Part I of Form S-3 under the Securities
  Act. Pursuant to Instruction C of Form S-8, the reoffer prospectus may be used for reoffers or resales of shares of common stock
  which are deemed to be "control securities" or "restricted securities" under the Securities Act that have
  been acquired by the selling stockholders named in the reoffer prospectus.
  Item 1. Plan
  Information.
  INmune Bio Inc. will provide each participant
  (the "Recipient") with documents that contain information related to the INmune Bio Inc. 2021 Equity Incentive Plan (the "2021
  Plan" or the "Plan"), and other information including, but not limited to, the disclosure required by Item 1 of Form
  S-8, which information is not filed as a part of this Registration Statement on Form S-8. The foregoing information and the documents
  incorporated by reference in response to Item 3 of Part II of this Registration Statement taken together constitute a prospectus that
  meets the requirements of Section 10(a) of the Securities Act. A Section 10(a) prospectus will be given to each Recipient who receives
  shares of common stock covered by this Registration Statement, in accordance with Rule 428(b)(1) under the Securities Act.
  Item 2. Registrant
  Information and Employee Plan Annual Information.
  We will provide to each Recipient a written
  statement advising it of the availability of documents incorporated by reference in Item 3 of Part II of this Registration Statement
  and of documents required to be delivered pursuant to Rule 428(b) under the Securities Act without charge and upon written or oral
  notice by contacting:
  INmune Bio Inc.
  225 NE Mizner Blvd., Suite
  640
  Boca Raton, FL 33432
  Attention: Corporate Secretary
  Telephone: (858) 964-3720
  Information required by Part I to be
  contained in Section 10(a) prospectus is omitted from the Registration Statement in accordance with Rule 428 under the Securities
  Act of 1933, and Note to Part I of Form S-8.
  1
  REOFFER PROSPECTUS
  INmune Bio Inc.
  4,000,000 Shares of Common Stock
  Issued or issuable under certain awards
  granted under the Plan
  This reoffer prospectus relates to the sale of
  4,000,000 shares of our common stock that may be offered and resold from time to time by the selling stockholders identified in this prospectus
  for their own account. Such shares have been or may be acquired in connection with awards granted under the INmune Bio Inc. 2021 Equity
  Incentive Plan (the "2021 Plan"). It is anticipated that the selling stockholders will offer shares for sale at prevailing
  prices on the NASDAQ Capital Market on the date of sale. We will receive no part of the proceeds from sales made under this reoffer prospectus.
  The selling stockholders will bear all sales commissions and similar expenses. Any other expenses incurred by us in connection with the
  registration and offering and not borne by the selling stockholders will be borne by us.
  This reoffer prospectus has been prepared
  for the purposes of registering the shares under the Securities Act of 1933, as amended (the "Securities Act") to allow
  for future sales by selling stockholders on a continuous or delayed basis to the public without restriction.
  The selling stockholders and any brokers
  executing selling orders on their behalf may be deemed to be "underwriters" within the meaning of the Securities Act,
  in which event commissions received by such brokers may be deemed to be underwriting commissions under the Securities Act.
  Our common stock is quoted on the NASDAQ Capital
  Market under the symbol "INMB." The last reported sale price of our common stock on the NASDAQ Capital Market on May 31, 2023,
  was $7.58 per share.
  We are an "emerging growth company"
  as that term is used in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and, as such, have elected to comply
  with certain reduced public company reporting requirements for this prospectus supplement, the accompanying prospectus and our
  filings with the Securities and Exchange Commission.
  Investing in our common stock involves a high degree of risk. See
  "Risk Factors" beginning on page 6 of this prospectus supplement.
  Neither the Securities and Exchange Commission nor any state
  securities commission has approved or disapproved of these securities or determined if this prospectus supplement is truthful or
  complete. Any representation to the contrary is a criminal offense.
  The date of this prospectus is June 20,
  2023.
  2
  TABLE OF CONTENTS
  Page
  Prospectus Summary
  4
  Risk Factors
  6
  Cautionary Note Regarding Forward Looking Statements
  7
  Use of Proceeds
  7
  Selling Stockholders
  7
  Plan of Distribution
  10
  Legal Matters
  12
  Experts
  12
  Incorporation of Certain Documents by Reference
  12
  Disclosure of Commission Position on Indemnification For Securities Act Liabilities
  13
  Additional Information Available to You
  14
  NO PERSON HAS BEEN AUTHORIZED TO GIVE ANY INFORMATION OR TO MAKE ANY
  REPRESENTATIONS, OTHER THAN THOSE CONTAINED IN THIS PROSPECTUS, IN CONNECTION WITH THE OFFERING MADE HEREBY, AND, IF GIVEN OR MADE, SUCH
  INFORMATION OR REPRESENTATION MUST NOT BE RELIED UPON AS HAVING BEEN AUTHORIZED BY THE COMPANY OR ANY OTHER PERSON. NEITHER THE DELIVERY
  OF THIS PROSPECTUS NOR ANY SALE MADE HEREUNDER SHALL UNDER ANY CIRCUMSTANCES CREATE ANY IMPLICATION THAT THERE HAS BEEN NO CHANGE IN THE
  AFFAIRS OF THE COMPANY SINCE THE DATE HEREOF. THIS PROSPECTUS DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY
  ANY SECURITIES OFFERED HEREBY BY ANYONE IN ANY JURISDICTION IN WHICH SUCH OFFER OR SOLICITATION IS NOT AUTHORIZED OR IN WHICH THE PERSON
  MAKING SUCH OFFER OR SOLICITATION IS NOT QUALIFIED TO DO SO OR TO ANY PERSON TO WHOM IT IS UNLAWFUL TO MAKE SUCH OFFER OR SOLICITATION.
  3
  PROSPECTUS SUMMARY
  This summary highlights information contained
  elsewhere in this prospectus. You should read the entire prospectus carefully, including the section entitled "Risk Factors"
  before deciding to invest in our common stock. In this prospectus, the "Company," "we," "us" and "our"
  refer to INmune Bio Inc. and its subsidiaries.
  Our objective is to develop and commercialize our product candidates
  to treat diseases where the innate immune system is not functioning normally and contributing to the patient's disease. This can
  be in cancer where Natural Killer ("NK") cells are inactive and contribute to a tumor's evasion of the immune system
  and/or disease progression while expression of MUC4 and immunosuppressive cells of the tumor microenvironment proliferate to protect the
  tumor from attack by the patient's immune system or this can be other diseases such as neurologic and metabolic diseases where chronic
  inflammation results in innate immune system dysfunction. Our initial focus will be the treatment of cancer, treatment of Alzheimer's
  Disease ("AD"), and the treatment of Treatment Resistant Depression ("TRD"). In cancer, we plan to pursue two
  parallel development programs: (1) with INKmune we will initially focus on treating men with castration resistant prostate cancer and
  patients with high-risk myelodysplastic syndrome (high risk MDS); (2) with INB03, we will treat patients with cancers that express MUC4,
  a mucinous polyglucan on the surface of some epithelial cancer cells, that appears to predict resistance to immunotherapy including women
  with MUC4 expressing HER2+ breast cancer. With our XPro1595 ("XPro") platform, we are developing therapeutics for Alzheimer's
  Disease and TRD. XPro for AD has completed Phase I trials and is currently enrolling patients in a Phase II trial. XPro for TRD is being
  prepared for Phase II trials. During 2021, we closed our Phase II clinical trial for treatment of pulmonary complications due to COVID-19
  infection as the Company determined it was a high-risk, low reward program due to the development of vaccinations and therapies which
  were not available when we started the clinical trial. The principal components of our strategy to achieve this objective are to:
  ●
  pursue development strategies and regulatory approval pathways that allow the treatment of oncology patients with our lead product candidates, INKmune and INB03;
  ●
  pursue development strategies and regulatory approval pathways that allow the treatment of neurodegenerative diseases in patients with our lead product candidates, XPro;
  ●
  adopt a product development strategy that solidifies our existing intellectual property ("IP") to prevent competition and expand our IP suite into related immunotherapeutic areas;
  ●
  provide clear value propositions to third-party payers, such as managed care companies or government programs like Medicare, to merit reimbursement for our product candidates; and
  ●
  Collaborate with other pharmaceutical companies with respect to, among
  other things, our INKmune and XPro platforms and other products that will benefit from development or marketing beyond our current resources.
  Pursue development and regulatory approval
  pathways.
  We believe INKmune, INB03 and XPro may be approvable under pathways that are potentially shorter than those typically available
  for drug products based on novel active ingredients, including as an orphan drug under the Orphan Drug Act and approval under the Food
  and Drug Administration (the "FDA") Accelerated Approval Program (see "Government Regulation"). We have not yet
  had a discussion with the Medicines and Healthcare Products Regulatory Agency ("MHRA") and/or FDA regarding such designation,
  but plan to do so in the future. We believe the INKmune MDS cancer program may qualify for orphan status. We believe that it would take
  a minimum of six months to receive Orphan Drug status once we submit an application and a minimum of 12 months to receive a designation
  once we submit an application. We might never have these discussions, submit applications under the Orphan Drug Act as the FDA Accelerated
  Approval Program or have these applications approved if we do.
  Adopt a two-pronged patent strategy.
  We
  are pursuing a two-pronged product development strategy that will seek to solidify our existing IP to prevent competition and expand our
  IP suite into related therapeutic areas. We are confident that our core in-licensed IP (see "Intellectual Property") will
  allow us both freedom-to-operate and provide robust protection from outside competition. We will continue to invest in expanding our patent
  suite. We will also seek to further to strengthen our IP position by looking to in-license IP related to our focus on the innate immune
  system.
  4
  Provide clear value propositions to third-party
  payors to merit reimbursement for our product candidates
  . We are designing our clinical development programs to demonstrate compelling,
  competitive advantages to patients and prescribers, and to demonstrate value propositions to third-party payors. We believe the use of
  INKmune and/or INB03 in patients with a high risk of tumor progression and death from tumor should prolong survival, improve the patient's
  quality of life and decrease the total cost of care for patients with these lethal malignancies. At the patient level, we believe INKmune
  and INB03 therapy, once approved, should improve survival and quality of life. At the payor level, we believe INKmune, once approved,
  should provide more predictable costs and outcomes. Therapies for Alzheimer's disease are needed for medical, social and economic
  reasons. The cost of Alzheimer's disease to the government is large and growing. The cost to families and care givers is real and
  burdensome. We believe treatment of patients with dementia, including Alzheimer's disease, may provide a strategy to alter the costly
  dynamic of this disease in society today.
  Collaborate to maximize the value of our technology
  .
  We believe there are two reasons for us to enter collaborations with other companies. The first is the further development of INKmune,
  INB03 and XPro by either providing additional innovations to the product, including combination therapy strategies, and/or providing resources
  to improve the speed and breadth of the development process. The second is to optimize the commercialization of our products either globally
  or regionally. The ideal partner will benefit us in both ways.
  We continue to look for ways to utilize our
  unique capabilities to optimize clinical application of cell therapies. We believe that we have identified a way to manufacture
  human mesenchymal stem cells for the medical research and biotech community that offers large volumes of high-quality, low passage
  human umbilical cord mesenchymal stem cells with minimal batch-to-batch variability. We believe this may solve the problem
  associated with supplying an adequate supply of human mesenchymal stem cells for clinical applications. We have established a
  reliable supply of human umbilical cords based on our agreement with the Anthony Nolan Cord Blood Bank in the United Kingdom. We
  have developed a validated manufacturing process that reliably produces contract manufacturer of the clinical grade
  ("cGMP") quality mesenchymal stem cells that we call CORDstrom. The manufacturing process can be performed at a contract
  manufacturing site under the direction of Mark Lowdell, the Company's Chief Scientific Officer (CSO). We will seek academic
  laboratories and biopharma companies who need a reliable source of high quality pooled human umbilical cord mesenchymal stem cells
  for research of and development of clinical products. Once identified, we plan to act as a cGMP for the development of therapeutic
  products by utilizing contract manufacturers. Because the production of the product is not continuous, we do not expect to engage a
  contract manufacturer until we have a customer identified. To date, we are supporting two academic clinical trials with CORDstrom.
  One program is a Phase 2 trial sponsored by the Great Ormond Street Children's Hospital in the UK treating children with
  erythematous bullousa, a disfiguring skin disease in children that is similar to a second degree burn and the second program is
  treatment of system lupus in adults. Both these studies are ongoing. INmune Bio is supplying the clinical product for treatment of
  these patients. The Company does not know the results of these trials until they are announced by the principal investigators at the
  clinical sites. We have identified contract manufacturers in the UK that have the capability to produce cGMP stem cells. We expect
  the commercial arrangement with academic laboratories or biopharma companies to be a combination of fee-for-service and licensing
  that does not require additional investment by us. We will be opportunistic in pursuing therapeutic opportunities for our own
  portfolio with this platform in the future if resources become available. The regulatory path for therapeutic applications of the
  mesenchymal stem cell products is well established and similar to the regulatory approval process for other cell therapies. We will
  only be responsible for regulatory compliance related to manufacturing of the mesenchymal stem cells when the product is being
  developed by a third party. When developing a therapeutic product for the Company's commercial portfolio, the Company will be
  responsible for all aspects of the regulatory process.
  As previously announced
  by the Company in a press release dated on May 23, 2022, the FDA placed a full clinical hold on XPro, requesting additional information
  around the Company's chemistry manufacturing and controls for the treatment. The Company is working with the regulatory body to
  have the current hold removed as soon as possible, but it is not yet clear when the hold will be lifted.
  If
  the FDA does not lift the clinical hold in a timely manner, or at all, our long-term development timeline for
  XPro
  and
  our business, financial condition or results of operations, may be adversely affected. The trial for XPro in Alzheimer's disease
  is currently open in Australia and Canada.
  Corporate Information
  We were incorporated under the laws of the State
  of Nevada on September 25, 2015. Our principal executive office is located at 225 NE Mizner Blvd, Suite 640, Boca Raton FL 33432 and our
  telephone number is (858) 964-3720.
  About
  This Offering
  This offering relates to the
  resale by the selling stockholders of up to 4,000,000 shares of common stock issued or issuable upon exercise of options issued pursuant
  to grants made pursuant to our 2021 Plan.
  5
  RISK FACTORS
  I Investing in our securities involves a high
  degree of risk. Before making an investment decision, you should consider carefully the risks, uncertainties and other factors described
  in our most recent Annual Report on Form 10-K, as supplemented and updated by subsequent quarterly reports on Form 10-Q and current reports
  on Form 8-K that we have filed or will file with the SEC.
  You should carefully
  consider the factors discussed in Part I, Item 1A. "Risk Factors" in our annual report on Form 10-K for the year
  ended December 31, 2022. There have been no material changes from those risk factors. The risks discussed in our 2022 annual report
  and described below could materially affect our business, financial condition and future results.
  6
  CAUTIONARY NOTE REGARDING FORWARD-LOOKING
  STATEMENTS
  This prospectus and the documents and information
  incorporated by reference in this prospectus contain certain forward-looking statements within the meaning of the Private Securities Litigation
  Reform Act of 1995. For this purpose, any statements contained in this prospect and the documents and information incorporated by reference
  in this prospectus that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing,
  words such as "may," "will," "expect," "believe," "anticipate," "estimate"
  or "continue" or comparable terminology are intended to identify forward-looking statements. These statements by their nature
  involve substantial risks and uncertainties, and actual results may differ materially depending on a variety of factors, many of which
  are not within our control. These factors include but are not limited to economic conditions generally and in the industries in which
  we may participate; competition within our chosen industry, including competition from much larger competitors; technological advances
  and failure to successfully develop business relationships.
  USE OF PROCEEDS
  We will not receive any
  proceeds from the sale of shares of common stock offered by the selling stockholders.
  SELLING STOCKHOLDERS
  This offering
  relates to the resale by the selling stockholders who have received or acquired, or may hereafter receive or acquire, the shares pursuant
  to the Plan. The selling stockholders may resell all, a portion, or none of the shares of common stock from time to time.
  The following table sets forth, based on information
  provided to us by the selling stockholders or known to us, the name of each selling stockholder, the nature of any position, office or
  other material relationship, if any, which the selling stockholder has had, within the past three years, with us or with any of our predecessors
  or affiliates, and the number of shares of our common stock beneficially owned by the selling stockholder before this offering. Except
  as otherwise indicated, the selling stockholders are past or present employees or consultants of the Company. The number of shares owned
  are those beneficially owned, as determined under the rules of the SEC, and the information is not necessarily indicative of beneficial
  ownership for any other purpose. Under these rules, beneficial ownership includes any shares of common stock as to which a person
  has sole or shared voting power or investment power and any shares of common stock which the person has the right to acquire within 60
  days through the exercise of any option, warrant or right, through conversion of any security or pursuant to the automatic termination
  of a power of attorney or revocation of a trust, discretionary account or similar arrangement. None of the selling stockholders is a broker-dealer
  or an affiliate of a broker-dealer. Percentage of ownership is based on 17,945,995 shares of common stock outstanding on June 5, 2023.
  We have assumed all shares of common stock reflected on the table will
  be sold from time to time in the offering covered by this prospectus. Because the selling stockholders may offer all or any portion
  of the shares of common stock listed in the table below, no estimate can be given as to the amount of those shares of common stock covered
  by this prospectus that will actually be held by the selling stockholders upon the termination of the offering. Selling stockholders may
  choose not to sell any of the shares of common stock registered herein.
  7
  Number of Shares
  Beneficially Owned
  Prior to Offering (1)
  Number of
  Shares Being
  Number of Shares
  Beneficially Owned
  After Offering
  Selling Stockholder
  Position
  Number
  Percent
  (%)
  Offered
  Number
  Percent
  (%)
  Raymond J. Tesi
  President, CEO and Director
  2,322,364
  12.4
  %
  94,581
  (2)
  2,227,783
  11.9
  %
  David Moss
  CFO, Treasurer and Secretary
  2,056,817
  11.0
  %
  94,581
  (2)
  1,962,236
  10.5
  %
  Mark Lowdell
  CSO
  2,122,605
  11.4
  %
  46,222
  (3)
  2,076,383
  11.2
  %
  Christopher Barnum
  Head of Neuroscience
  293,333
  1.6
  %
  93,333
  (4)
  200,000
  1.1
  %
  Josh Schoonover
  Assoc. General Counsel
  281,266
  1.5
  %
  86,666
  (5)
  194,600
  1.1
  %
  Cory Ellspermann
  Controller and VP of Finance
  115,917
  *
  40,000
  (6)
  75,917
  *
  Tara Lehner
  VP of Clinical Operations
  54,667
  *
  54,667
  (7)
  -
  *
  Parris Pope
  Head of Medical Affairs
  38,889
  *
  38,889
  (8)
  -
  *
  Kim Staats
  Director of Rare Disease Drug Development
  25,000
  *
  25,000
  (9)
  -
  *
  Gary Cai
  Vice President of Regulatory Affairs
  10,833
  *
  10,833
  (10)
  -
  *
  Scott Juda
  Director
  287,550
  1.6
  %
  28,238
  (11)
  259,312
  1.4
  %
  Timothy Schroeder
  Director
  349,737
  1.9
  %
  28,238
  (11)
  321,499
  1.8
  %
  J. Kelly Ganjei
  Director
  275,343
  1.5
  %
  28,238
  (11)
  247,105
  1.4
  %
  Edgardo Baracchini
  Director
  149,550
  *
  28,238
  (11)
  121,312
  *
  Marcia Allen
  Director
  149,550
  *
  28,238
  (11)
  121,312
  *
  Total
  8,533,421
  725,962
  7,807,459
  *
  Less than 1%
  (1)
  The securities "beneficially owned" by a person
  are determined in accordance with the definition of "beneficial ownership" set forth in the rules and regulations promulgated
  under the Exchange Act, and accordingly, may include securities owned by and for, among others, the spouse and/or minor children of an
  individual and any other relative who has the same home as such individual, as well as other securities as to which the individual has
  or shares voting or investment power or which such person has the right to acquire within 60 days of June 5, 2023 pursuant to the
  exercise of options, or otherwise. Beneficial ownership may be disclaimed as to certain of the securities.
  (2)
  Includes: (a) options to purchase 70,663 shares of common stock exercisable at an exercise price of $17.49 per share pursuant to the 2021 Plan, of which options to purchase 36,803 shares are vested and (b) options to purchase 130,000 shares of common stock exercisable at an exercise price of $7.92 per share pursuant to the 2021 Plan, of which options to purchase 57,778 shares are vested.
  (3)
  Includes options to purchase 104,000 shares of common stock exercisable at an exercise price of $7.92 per share pursuant to the 2021 Plan, of which options to purchase 46,222 shares are vested.
  (4)
  Includes: (a) options to purchase 100,000 shares of common stock exercisable at an exercise price of $21.06 per share pursuant to the 2021 Plan, of which options to purchase 66,667 shares are vested; and (b) options to purchase 60,000 shares of common stock at an exercise price of $7.92 per share pursuant to the 2021 Plan, of which options to purchase 26,666 shares are vested.
  (5)
  Includes: (a) options to purchase 90,000 shares of common stock exercisable at an exercise price of $21.06 per share pursuant to the 2021 Plan, of which options to purchase 60,000 shares are vested; and (b) options to purchase 60,000 shares of common stock at an exercise price of $7.92 per share pursuant to the 2021 Plan, of which options to purchase 26,666 shares are vested.
  8
  (6)
  Includes: (a) options to purchase 40,000 shares of common
  stock exercisable at an exercise price of $21.06 per share pursuant to the 2021 Plan, of which options to purchase 26,666 shares are
  vested and (b) options to purchase 30,000 shares of common stock exercisable at an exercise price of $7.92 per share pursuant to the
  2021 Plan, of which options to purchase 13,334 shares are vested.
  (7)
  Includes: a) options to purchase 58,000 shares of common
  stock exercisable at an exercise price of $18.40 per share pursuant to the 2021 Plan, of which options to purchase 45,778 shares are
  vested and (b) options to purchase 20,000 shares of common stock exercisable at an exercise price of $7.92 per share pursuant to the
  2021 Plan, of which options to purchase 8,889 shares are vested.
  (8)
  Includes: a) options to purchase 45,000 shares of common
  stock exercisable at an exercise price of $21.06 per share pursuant to the 2021 Plan, of which options to purchase 30,000 shares are
  vested and (b) options to purchase 30,000 shares of common stock exercisable at an exercise price of $7.92 per share pursuant to the
  2021 Plan, of which options to purchase 8,889 shares are vested.
  (9)
  Includes options to purchase 50,000 shares of common stock
  exercisable at an exercise price of $9.67 per share pursuant to the 2021 Plan of which options to purchase 25,000 shares are vested.
  (10)
  Includes options to purchase 30,000 shares of common stock
  exercisable at an exercise price of $7.36 per share pursuant to the 2021 Plan of which options to purchase 10,833 shares are vested.
  (11)
  Includes: (a) options to purchase 19,025 shares of common
  stock exercisable by pursuant to the 2021 Plan, of which options to purchase 12,683 shares are vested and (b) options to purchase 35,000
  shares of common stock exercisable at an exercise price of $7.92 per share pursuant to the 2021 Plan, of which options to purchase 15,555
  shares are vested.
  9
  PLAN OF DISTRIBUTION
  Timing of Sales
  The
  selling stockholders may offer and sell the shares covered by this prospectus at various times. The selling stockholders will act
  independently of our company in making decisions with respect to the timing, manner and size of each sale.
  To our knowledge, no selling stockholder has
  any agreement or understanding, directly or indirectly, with any person to resell the shares of common stock covered by this prospectus.
  Offering Price
  The sales price offered by the selling
  stockholders to the public may be:
  1.
  the market price prevailing at the time of sale;
  2.
  a price related to such prevailing market price; or
  3.
  such other price as the selling stockholders determine from time to time.
  Manner of Sale
  The shares of common stock may be sold
  by means of one or more of the following methods:
  1.
  a block trade in which the broker-dealer so engaged will attempt to sell the shares of common stock as agent, but may position and resell a portion of the block as principal to facilitate the transaction;
  2.
  purchases by a broker-dealer as principal and resale by that broker-dealer for its account pursuant to this prospectus;
  3.
  ordinary brokerage transactions in which the broker solicits purchasers;
  4.
  through options, swaps or derivatives;
  5.
  in transactions to cover short sales;
  6.
  privately negotiated transactions; or
  7.
  in a combination of any of the above methods.
  The selling stockholders may sell their
  shares of common stock directly to purchasers or may use brokers, dealers, underwriters or agents to sell their shares of common
  stock. Brokers or dealers engaged by the selling stockholders may arrange for other brokers or dealers to participate. Brokers
  or dealers may receive commissions, discounts or concessions from the selling stockholders, or, if any such broker-dealer acts
  as agent for the purchaser of shares of common stock, from the purchaser in amounts to be negotiated immediately prior to the sale.
  The compensation received by brokers or dealers may, but is not expected to, exceed that which is customary for the types of transactions
  involved.
  Broker-dealers may agree with a selling stockholder to sell a specified
  number of shares of common stock at a stipulated price per common share, and, to the extent the broker-dealer is unable to do so acting
  as agent for a selling stockholder, to purchase as principal any unsold shares of common stock at the price required to fulfill the broker-dealer
  commitment to the selling stockholder.
  Broker-dealers who acquire shares of common
  stock as principal may thereafter resell the shares of common stock from time to time in transactions, which may involve block
  transactions and sales to and through other broker-dealers, including transactions of the nature described above, on the NASDAQ
  Capital Market or otherwise at prices and on terms then prevailing at the time of sale, at prices then related to the then-current
  market price or in negotiated transactions. In connection with resales of the shares of common stock, broker-dealers may pay to
  or receive from the purchasers of shares commissions as described above.
  10
  If the selling stockholders enter into
  arrangements with brokers or dealers, as described above, we are obligated to file a post-effective amendment to this registration
  statement disclosing such arrangements, including the names of any broker-dealers acting as underwriters.
  The selling stockholders and any broker-dealers
  or agents that participate with the selling stockholders in the sale of the shares of common stock may be deemed to be "underwriters"
  within the meaning of the Securities Act. In that event, any commissions received by broker-dealers or agents and any profit on
  the resale of the shares of common stock purchased by them may be deemed to be underwriting commissions or discounts under the
  Securities Act.
  Sales Pursuant to Rule 144
  Any shares of common stock covered by this
  prospectus which qualify for sale pursuant to Rule 144 under the Securities Act may be sold under Rule 144 rather than pursuant
  to this prospectus.
  Regulation M
  The selling stockholders must comply with
  the requirements of the Securities Act and the Securities Exchange Act of 1934, as amended (the "Exchange Act") in
  the offer and sale of the common stock. In particular we will advise the selling stockholders that the anti-manipulation rules
  of Regulation M under the Exchange Act may apply to sales of shares of common stock in the market and to the activities of
  the selling stockholders and their affiliates. Regulation M under the Exchange Act prohibits, with certain exceptions, participants
  in a distribution from bidding for, or purchasing for an account in which the participant has a beneficial interest, any of the
  securities that are the subject of the distribution.
  Accordingly, during such times as a selling
  stockholder may be deemed to be engaged in a distribution of the common stock, and therefore be considered to be an underwriter,
  the selling stockholder must comply with applicable law and, among other things:
  1.
  may not engage in any stabilization activities in connection with our common stock;
  2.
  may not cover short sales by purchasing shares while the distribution is taking place; and
  3.
  may not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities other than as permitted under the Exchange Act.
  In addition, we will make copies of this
  prospectus available to the selling stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities
  Act.
  State Securities Laws
  Under the securities laws of some states,
  the shares of common stock may be sold in such states only through registered or licensed brokers or dealers. In addition, in some
  states the shares of common stock may not be sold unless the shares have been registered or qualified for sale in the state or
  an exemption from registration or qualification is available and is complied with.
  Expenses of Registration
  We are bearing all costs relating to the
  registration of the common stock. The selling stockholders, however, will pay any commissions or other fees payable to brokers
  or dealers in connection with any sale of the common stock.
  11
  LEGAL MATTERS
  The validity of the common stock has been
  passed upon by Sichenzia Ross Ference LLP, New York, New York.
  EXPERTS
  The consolidated financial statements of INmune
  Bio Inc. as of and for the years ended December 31, 2022 and 2021 appearing in INmune Bio Inc.'s Definitive Proxy Statement
  on Schedule A for the year ended December 31, 2022, have been audited by Marcum LLP, as set forth in its report thereon, included
  therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance
  upon such report given on the authority of such firm as experts in accounting and auditing.
  INCORPORATION
  OF CERTAIN DOCUMENTS by Reference
  The Securities and Exchange Commission, or SEC,
  allows us to incorporate by reference certain of our publicly filed documents into this prospectus, which means that such information
  is considered part of this prospectus. Information that we file with the SEC subsequent to the date of this prospectus will automatically
  update and supersede this information. We incorporate by reference the documents listed below and any future filings made with the SEC
  under all documents subsequently filed by us pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act until the selling stockholders
  have sold all of the shares offered hereby or such shares have been deregistered.
  ●
  our Annual Report on
  Form 10-K
  for the fiscal year ended December 31, 2022, filed with the SEC on March 2, 2023;
  ●
  our Quarterly Report on
  Form 10-Q
  for the period ended March 31, 2023, filed with the SEC on May 3, 2023;
  ●
  our Current Reports on Form 8-K or Form 8-K/A filed with the SEC on
  January
      25, 2023
  ,
  February
      10, 2023
  ,
  February
      22, 2023
  ,
  February
      22, 2023
  ,
  March 15,
      2023
  ,
  April 3,
      2023
  ,
  April 11,
      2023
  ,
  April 20,
      2023
  ,
  April 24,
      2023
  ,
  May 8, 2023
  ,
  May 12, 2023
  , and
  June 1, 2023
  .
  ●
  our Definitive Proxy Statement on
  Schedule 14A
  filed with the SEC on April 21, 2023; and
  ●
  the description of our common stock, which is contained in the registration statement on
  Form 8-A
  filed with the SEC on February 1, 2019 (File No. 001-38793), including any amendments or reports filed for the purpose of updating that description.
  Notwithstanding the foregoing, information furnished
  under Items 2.02 and 7.01 of any Current Report on Form 8-K, including the related exhibits, is not incorporated by reference in this
  Registration Statement.
  12
  Disclosure
  Of Commission Position On Indemnification
  For
  Securities Act Liabilities
  NRS 78.7502(1) provides that a corporation may
  indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or
  proceeding, whether civil, criminal, administrative or investigative, except an action by or in the right of the corporation, by reason
  of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation
  as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses,
  including attorneys' fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection
  with the action, suit or proceeding if he: (a) is not liable pursuant to NRS 78.138; or (b) acted in good faith and in a manner which
  he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding,
  had no reasonable cause to believe his conduct was unlawful.
  NRS Section 78.7502(2) provides that a corporation
  may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit
  by or in the right of the corporation to procure a judgment in its favor by reason of the fact that he is or was a director, officer,
  employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent
  of another corporation, partnership, joint venture, trust or other enterprise against expenses, including amounts paid in settlement and
  attorneys' fees actually and reasonably incurred by him in connection with the defense or settlement of the action or suit if he:
  (a) is not liable pursuant to NRS 78.138; or (b) acted in good faith and in a manner which he reasonably believed to be in or not opposed
  to the best interests of the corporation. Indemnification may not be made for any claim, issue or matter as to which such a person has
  been adjudged by a court of competent jurisdiction, after exhaustion of all appeals there from, to be liable to the corporation or for
  amounts paid in settlement to the corporation, unless and only to the extent that the court in which the action or suit was brought or
  other court of competent jurisdiction determines upon application that in view of all the circumstances of the case, the person is fairly
  and reasonably entitled to indemnity for such expenses as the court deems proper.
  Our Articles of Incorporation provides that every
  person who was or is a party to, or is threatened to be made a party to, or is involved in any action, suit or proceeding, whether civil,
  criminal, administrative or investigative, by reason of the fact that he, or a person of whom he is the legal representative, is or was
  a director or officer of the Company, or is or was serving at the request of the Company as a director or officer of another corporation,
  or as its representative in a partnership, joint venture, trust or other enterprise, shall be indemnified and held harmless to the fullest
  extent legally permissible under the laws of the State of Nevada from time to time against all expenses, liability and loss (including
  attorney's fees, judgements, fines and amounts paid or to be paid in settlement) reasonably incurred or suffered by him in connection
  therewith. Such right of indemnification shall be a contract right which may be enforced in any matter desired by such person. The expenses
  of the officers and directors incurred in defending a civil or criminal action, suit or proceeding must be paid by the Company as they
  are incurred and in advance of the final disposition of the action, suit or proceeding, upon receipt of an undertaking by or on behalf
  of the director or officer to repay the amount if it is ultimately determined by a court of competent jurisdiction that he is not entitled
  to be indemnified by the Company. Such right of indemnification shall not be exclusive of any other right which such directors, officers
  or representatives may have or hereafter acquire, and, without limiting the generality of such statement, they shall be entitled to their
  respective rights of indemnification under any bylaw, agreement, vote of stockholders, provision of law, or otherwise, as well as their
  rights under this Article.
  NRS Section 78.747 provides that except as otherwise
  provided by specific statute, no director or officer of a corporation is individually liable for a debt or liability of the corporation,
  unless the director or officer acts as the alter ego of the corporation. The court as a matter of law must determine the question of whether
  a director or officer acts as the alter ego of a corporation.
  Insofar as indemnification for liabilities arising
  under the Securities Act may be permitted to directors, offices or controlling persons of ours, pursuant to the foregoing provisions,
  or otherwise, we have been advised that, in the opinion of the Securities and Exchange Commission, such indemnification is against public
  policy as expressed in the Securities Act, and is, therefore, unenforceable. In the event that a claim for indemnification against such
  liabilities (other than the payment by us of expenses incurred or paid by a director, officer or controlling person of ours in the successful
  defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities
  being registered hereunder, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit
  to a court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Securities
  Act and will be governed by the final adjudication of such issue.
  13
  Additional
  Information Available to You
  This prospectus is part of a Registration Statement
  on Form S-8 that we filed with the SEC. Certain information in the Registration Statement has been omitted from this prospectus in accordance
  with the rules of the SEC. We file annual, quarterly and special reports, proxy statements and other information with the SEC. You can
  inspect and copy the Registration Statement as well as reports, proxy statements and other information we have filed with the SEC at the
  public reference room maintained by the SEC at 100 F Street N.E. Washington, D.C. 20549, You can obtain copies from the public reference
  room of the SEC at 100 F Street N.E. Washington, D.C. 20549, upon payment of certain fees. You can call the SEC at 1-800-732-0330 for
  further information about the public reference room. We are also required to file electronic versions of these documents with the SEC,
  which may be accessed through the SEC's World Wide Web site at http://www.sec.gov. No dealer, salesperson or other person is authorized
  to give any information or to make any representations other than those contained in this prospectus, and, if given or made, such information
  or representations must not be relied upon as having been authorized by us. This prospectus does not constitute an offer to buy any security
  other than the securities offered by this prospectus, or an offer to sell or a solicitation of an offer to buy any securities by any person
  in any jurisdiction where such offer or solicitation is not authorized or is unlawful. Neither delivery of this prospectus nor any sale
  hereunder shall, under any circumstances, create any implication that there has been no change in the affairs of our company since the
  date hereof.
  14
  PART II
  INFORMATION REQUIRED IN THE REGISTRATION
  STATEMENT
  Item 3. Incorporation of Documents by
  Reference.
  The Securities and Exchange Commission, or SEC, allows
  us to incorporate by reference certain of our publicly filed documents into this prospectus, which means that such information is considered
  part of this prospectus. Information that we file with the SEC subsequent to the date of this prospectus will automatically update and
  supersede this information. We incorporate by reference the documents listed below and any future filings made with the SEC under all
  documents subsequently filed by us pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act until the selling stockholders have
  sold all of the shares offered hereby or such shares have been deregistered.
  ●
  our Annual Report on
  Form 10-K
  for the fiscal year ended December 31, 2022, filed with the SEC on March 2, 2023;
  ●
  our Quarterly Report on
  Form 10-Q
  for the period ended March 31, 2023, filed with the SEC on May 3, 2023;
  ●
  our Current Reports on Form 8-K or Form 8-K/A filed with the SEC on
  January
      25, 2023
  ,
  February
      10, 2023
  ,
  February
      22, 2023
  ,
  February
      22, 2023
  ,
  March 15,
      2023
  ,
  April 3,
      2023
  ,
  April 11,
      2023
  ,
  April 20,
      2023
  ,
  April 24,
      2023
  ,
  May 8, 2023
  ,
  May 12, 2023
  , and
  June 1, 2023
  .
  ●
  our Definitive Proxy Statement on
  Schedule 14A
  filed with the SEC on April 21, 2023; and
  ●
  the description of our common stock, which is contained in the registration statement on
  Form 8-A
  filed with the SEC on February 1, 2019 (File No. 001-38793), including any amendments or reports filed for the purpose of updating that description.
  Notwithstanding the foregoing, information furnished
  under Items 2.02 and 7.01 of any Current Report on Form 8-K, including the related exhibits, is not incorporated by reference in this
  Registration Statement.
  Item 4. Description of Securities.
  Not applicable.
  Item 5. Interests of Named Experts and
  Counsel.
  None.
  II-
  1
  Item 6. Indemnification of Directors
  and Officers.
  NRS 78.7502(1) provides that a corporation may
  indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or
  proceeding, whether civil, criminal, administrative or investigative, except an action by or in the right of the corporation, by reason
  of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation
  as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses,
  including attorneys' fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection
  with the action, suit or proceeding if he: (a) is not liable pursuant to NRS 78.138; or (b) acted in good faith and in a manner which
  he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding,
  had no reasonable cause to believe his conduct was unlawful.
  NRS Section 78.7502(2) provides that a corporation
  may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit
  by or in the right of the corporation to procure a judgment in its favor by reason of the fact that he is or was a director, officer,
  employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent
  of another corporation, partnership, joint venture, trust or other enterprise against expenses, including amounts paid in settlement and
  attorneys' fees actually and reasonably incurred by him in connection with the defense or settlement of the action or suit if he:
  (a) is not liable pursuant to NRS 78.138; or (b) acted in good faith and in a manner which he reasonably believed to be in or not opposed
  to the best interests of the corporation. Indemnification may not be made for any claim, issue or matter as to which such a person has
  been adjudged by a court of competent jurisdiction, after exhaustion of all appeals there from, to be liable to the corporation or for
  amounts paid in settlement to the corporation, unless and only to the extent that the court in which the action or suit was brought or
  other court of competent jurisdiction determines upon application that in view of all the circumstances of the case, the person is fairly
  and reasonably entitled to indemnity for such expenses as the court deems proper.
  Our Articles of Incorporation provides that every
  person who was or is a party to, or is threatened to be made a party to, or is involved in any action, suit or proceeding, whether civil,
  criminal, administrative or investigative, by reason of the fact that he, or a person of whom he is the legal representative, is or was
  a director or officer of the Company, or is or was serving at the request of the Company as a director or officer of another corporation,
  or as its representative in a partnership, joint venture, trust or other enterprise, shall be indemnified and held harmless to the fullest
  extent legally permissible under the laws of the State of Nevada from time to time against all expenses, liability and loss (including
  attorney's fees, judgements, fines and amounts paid or to be paid in settlement) reasonably incurred or suffered by him in connection
  therewith. Such right of indemnification shall be a contract right which may be enforced in any matter desired by such person. The expenses
  of the officers and directors incurred in defending a civil or criminal action, suit or proceeding must be paid by the Company as they
  are incurred and in advance of the final disposition of the action, suit or proceeding, upon receipt of an undertaking by or on behalf
  of the director or officer to repay the amount if it is ultimately determined by a court of competent jurisdiction that he is not entitled
  to be indemnified by the Company. Such right of indemnification shall not be exclusive of any other right which such directors, officers
  or representatives may have or hereafter acquire, and, without limiting the generality of such statement, they shall be entitled to their
  respective rights of indemnification under any bylaw, agreement, vote of stockholders, provision of law, or otherwise, as well as their
  rights under this Article.
  NRS Section 78.747 provides that except as otherwise
  provided by specific statute, no director or officer of a corporation is individually liable for a debt or liability of the corporation,
  unless the director or officer acts as the alter ego of the corporation. The court as a matter of law must determine the question of whether
  a director or officer acts as the alter ego of a corporation.
  Insofar as indemnification for liabilities arising
  under the Securities Act may be permitted to directors, offices or controlling persons of ours, pursuant to the foregoing provisions,
  or otherwise, we have been advised that, in the opinion of the Securities and Exchange Commission, such indemnification is against public
  policy as expressed in the Securities Act, and is, therefore, unenforceable. In the event that a claim for indemnification against such
  liabilities (other than the payment by us of expenses incurred or paid by a director, officer or controlling person of ours in the successful
  defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities
  being registered hereunder, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit
  to a court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Securities
  Act and will be governed by the final adjudication of such issue.
  II-
  2
  Item 7. Exemption from Registration
  Claimed.
  Not applicable.
  Item 8. Exhibits.
  Exhibit Number
  Description
  5.1
  Opinion of Sichenzia Ross Ference LLP*
  23.1
  Consent of Marcum LLP*
  23.2
  Consent of Sichenzia Ross Ference LLP (included in Exhibit 5.1)*
  24.1
  Power of Attorney (included on the signature page)
  99.1
  INmune Bio Inc. 2021 Stock Incentive Plan (incorporated by reference to the Current Report on Form 8-K filed with the SEC on June 3, 2021).
  107
  Filing Fee Table*
  *
  Filed herewith
  Item 9. Undertakings.
  (a)
  The Company hereby undertakes:
  (1)
  To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
  (i)
  To include any prospectus required by Section 10(a)(3) of the Securities Act.
  (ii)
  To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered  would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective Registration Statement.
  II-
  3
  (iii)
  To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement; provided, however, that (A) paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the Registration Statement is on Form S–8 (§239.16b of Regulation S-K), and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Securities and Exchange Commission by the Company pursuant to section 13 or section 15(d) of the Exchange Act (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in the Registration Statement; and (B) paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) do not apply if the Registration Statement is on Form S-3 or Form F-3, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Securities and Exchange Commission by the Company pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the Registration Statement; provided further, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the Registration Statement is for an offering of asset-backed securities on Form S-1 or Form S-3, and the information required to be included in a post-effective amendment is provided pursuant to Item 1100(c) of Regulation AB.
  (2)
  That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
  (3)
  To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
  (4)
  That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:
  (A) Each prospectus
  filed by a Registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the
  filed prospectus was deemed part of and included in the registration statement; and
  (B) Each prospectus
  required to be filed pursuant to Rule 424(b)(2), (b)(5) or (b)(7) as part of a registration statement in reliance on Rule 430B
  relating to an offering made pursuant to Rule 415(a)(1)(i),  (vii) or (x) for the purpose of providing
  the information required by Section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration
  statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract
  of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the
  issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration
  statement relating to the securities in the registration statement to which the prospectus relates, and the offering of such securities
  at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration
  statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by
  reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with
  a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement
  or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.
  (b)
  The Company hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Company's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
  (c)
  Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Company pursuant to the foregoing provisions, or otherwise, the Company has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Company of expenses incurred or paid by a director, officer or controlling person of the Company in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Company will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
  II-
  4
  SIGNATURES
  Pursuant
  to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all
  of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned,
  thereunto duly authorized, in the City of Boca Raton, State of Florida, on June 20, 2023.
  INmune Bio Inc.
  /s/ Raymond J. Tesi
  Raymond J. Tesi, M. D.
  Chief Executive Officer
  (Principal Executive Officer)
  /s/ David J. Moss
  David J. Moss
  Chief Financial Officer
  (Principal Financial and Accounting Officer)
  II-
  5
  Each person whose signature appears below
  constitutes and appoints Raymond J. Tesi and David J. Moss, and each of them severally, as his true and lawful attorney in fact
  and agent, with full powers of substitution and re-substitution, for him and in his name, place and stead, in any and all capacities,
  to sign any or all amendments (including post effective amendments) to the Registration Statement, and to sign any registration
  statement for the same offering covered by this Registration Statement that is to be effective upon filing pursuant to Rule 462(b)
  under the Securities Act of 1933, as amended, and all post effective amendments thereto, and to file the same, with all exhibits
  thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact
  and agent, each acting alone, full power and authority to do and perform each and every act and thing requisite and necessary to
  be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying
  and confirming all that said attorney-in-fact and agent, each acting alone, or his or her substitute or substitutes, may lawfully
  do or cause to be done by virtue hereof.
  Pursuant to the requirements of the Securities
  Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the dates indicated.
  /s/ Raymond J. Tesi
  June 20, 2023
  Raymond J. Tesi, M.D.
  Chief Executive Officer and Director
  (principal executive officer)
  /s/ David J. Moss
  June 20, 2023
  David J. Moss
  Chief Financial Officer
  (principal financial and accounting officer)
  /s/ Timothy Schroeder
  June 20, 2023
  Timothy Schroeder
  Director
  /s/ J. Kelly Ganjei
  June 20, 2023
  J. Kelly Ganjei
  Director
  /s/ Scott Juda, JD
  June 20, 2023
  Scott Juda, JD
  Director
  /s/ Edgardo Baracchini
  June 20, 2023
  Edgardo Baracchini
  Director
  /s/ Marcia Allen
  June 20, 2023
  Marcia Allen
  Director
  II-
  6